I-FLICE, A NOVEL INHIBITOR OF TUMOR NECROSIS FACTOR RECEPTOR-1 AND CD-95 INDUCED APOPTOSIS

Abstract: The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of TNFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE-2 protein. I-FLICE-1 or I-FLICE-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of I-FLICE-1 or I-FLICE-2 activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis.

Description: I-FLICE, A NOVEL INHIBITOR OF TUMOR NECROSIS FACTOR RECEPTOR-1 AND CD-95 INDUCED APOPTOSIS Background of the Invention Field of the Invention The present invention relates to a novel inhibitor of TNFR-1 and CD-95 induced apoptosis. More specifically, isolated nucleic acid molecules are provided encoding a human I-FLICE (Inhibitor of FLICE (FADD-like ICE)) polynucleotides. I-FLICE polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of I-FLICE activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis. Related Art The cell death machinery is conserved throughout evolution and is composed of activators, inhibitors, and effectors (Chinnaiyan, A.M. and Dixit, V.M., Curr. Blol. 6:555-562 (1996)). The effector arm of the cell death pathway is composed of a rapidly growing family of cysteine aspartate-specific proteases termed caspases (Alnemri, E.S., et al., Cell 87:171 (1996)). As implied by the name, these cysteine proteases cleave substrates following an aspartate residue (Alnemri, E.S., et al., Cell 87:171 (1996); Walker, N.P., et al, Cell 75:343-352 (1994)). Caspases are normally present as single polypeptide zymogens and contain an amino-terminal prodomain, and large and small catalytic subunits (Wilson, K.P., et al., Nature 370:270-274 (1994); Rotonda, J., et al., Nat. Struct. Biol. 5:619-625 (1996); Fraser, A. and Evan, G., Cell 55:781-784 (1996)). The two chain active enzyme (composed of the large and small subunits) is obtained following proteolytic processing at internal Asp residues (Wilson, K.P., et al., Nature 370:270-274 (1994); Rotonda, J., et al., Nat. Struct. Biol. 5:619-625 (1996); Fraser, A. and Evan, G., Cell 55:781-784 (1996)). As such, caspases are capable of activating each other in a manner analogous to zymogen activation that is observed in the coagulation cascade (Boldin, M.P., et al., Cell #5:805-815 (1996)). The identification of FLICE and Mch4/FLICE2 as receptor associated caspases suggested a suφrisingly direct mechanism for activation of the death pathway by the cytotoxic receptors CD-95 and TNFR-1 (Boldin, M.P., et al., Cell 55:805-815 (1996); Muzio, M., et al., Cell 55:817-827 (1996); Vincenz, C. and Dixit, V.M., J Biol. Chem. 272:6578-6583 (1997); Chinnaiyan, A.M., et al., Cell 57:505-512 (1995)). Upon activation, both receptors use their death domains to bind the corresponding domain in the adaptor molecule FADD (Fas-associated death domain protein) (Muzio, M., et al, Cell 55:817-827 (1996); Vincenz, C. and Dixit, V.M., J Biol. Chem. 272:6578-6583 (1997); Chinnaiyan, A.M., et al., Cell 57:505-512 (1995)). Dominant negative versions of FADD that lack the N- terminal segment but still retain the death domain potently inhibit both CD-95 and TNFR-1 induced apoptosis (Chinnaiyan, A.M., et al., J. Biol. Chem. 277:4961-4965 (1996); Muzio, M., et al., J Biol. Chem. 272:2952-2956 (1997)). Given the importance of the N-terminal segment in engaging the death pathway, it has been termed the death effector domain (DED) (Chinnaiyan, A.M., et al, J. Biol. Chem. 277:4961-4965 (1996)). Remarkably, the DED is present within the prodomain of FLICE and Mch4/FLICE2 and mutagenesis studies suggest that a homophilic interaction between the DED of FADD and the corresponding domain in FLICE or Mch4/FLICE2 is responsible for the recruitment of these proteases to the CD-95 and TNFR-1 signalling complexes (Muzio, M., et al, Cell 55:817-827 (1996); Vincenz, C. and Dixit, VM., J. Biol. Chem. 272:6578-6583 (1997); Chinnaiyan, A.M., et al., Cell 57:505-512 (1995); Chinnaiyan, A.M., et al., J. Biol. Chem. 277:4961-4965 (1996)). Taken together, these data are consistent with FLICE and Mch4/FLICE2 being apical enzymes that initiate precipitous proteolytic processing of downstream caspases resulting in apoptosis (Boldin, M.P., et al., Cell 55:805-815 (1996); Srinivasula, S.M., et al., PN S 95:14486-14491 (1996); Fernandes-Alnemri, T., et al., PNAS 93:7464-7469 (1996); Henkart, P.A., Immunity 4: 195-201 (1996)). A number of viral gene products antagonize CD-95 and TNFR-1 mediated killing as a means to persist in the infected host (Shen, Y. and Shenk, T.S., Current Opinion in Genetics and Development 5:105-111 (1995)). The poxvirus encoded serpin CrmA and baculovirus gene product p35 are direct caspase inhibitors (Walker, N.P., et al., Cell 75:343-352 (1994)). In contrast, the molluscum contagiosum virus protein MC 159 and the equine heφes virus protein E8 encode DED-containing decoy molecules that bind to either FADD (MCI 59) or FLICE (E8) and disrupt assembly of the receptor signalling complex, thereby abrogating the death signal (Hu, S., et al., J. Biol. Chem. 272:9621-9624 (1997); Bertin, J., et al., PNAS94 172-1176 (1997); Thome, ML, et al, Nature 386:527-521 (1997)). The existence of these viral inhibitors has raised the question of whether functionally equivalent molecules are encoded in the mammalian genome. There is a need for factors, such as the polypeptides of the present invention, that are useful for inhibiting apoptosis for therapeutic puφoses, for example, in the treatment of Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock, sepsis, stroke, CNS inflammation, osteoporosis, ischemia, reperfusion injury, cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis of endothelial cells in cardiovascular disease, degenerative liver disease, MS and head injury damage. There is a need, therefore, for the identification and characterization of such factors that are inhibitors of apoptosis, such as the I-FLICE- 1 and I-FLICE-2 polypeptides of the present invention, which can play a role in preventing, ameliorating or correcting the diseases and disorders associated with apoptosis. Summary of the Invention The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding the I-FLICE- 1 polypeptide having the amino acid sequence shown in SEQ ID NO:2 or the amino acid sequence encoded by the cDNA clone deposited in a bacterial host as ATCC Deposit Number 209038 on May 15, 1997. The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding the I-FLICE-2 polypeptide having the amino acid sequence shown in SEQ ID NO:6 or the amino acid sequence encoded by the cDNA clone deposited in a bacterial host as ATCC Deposit Number 209041 on May 15, 1997. The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant vectors, as well as to methods of making such vectors and host cells and for using them for production of I-FLICE- 1 or I-FLICE-2 polypeptides or peptides by recombinant techniques. The invention further provides an isolated I-FLICE- 1 or I-FLICE-2 polypeptides having an amino acid sequence encoded by the polynucleotides described herein. The invention further provides a diagnostic method useful during diagnosis or prognosis of a disease states resulting from aberrant cell proliferation due to alterations in I-FLICE- 1 or I-FLICE-2 expression. The present invention also provides a screening method for determining whether a candidate agonist or antagonist is capable of enhancing or inhibiting a cellular activity of either an I-FLICE- 1 or I-FLICE-2 polypeptide. The method involves contacting cells which express one or both of the I-FLICE- 1 or I-FLICE- 2 polypeptides with a candidate compound, assaying a cellular response, and comparing the cellular response to a standard cellular response, the standard being assayed in absence of the candidate compound, whereby an increased cellular response over the standard indicates that the candidate compound is an agonist of the polypeptide activity and a decreased cellular response compared to the standard indicates that the candidate compound is an antagonist of the activity. An additional aspect of the invention is related to a method for treating an individual in need of an increased level of I-FLICE- 1 or I-FLICE-2 activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an isolated I-FLICE- 1 or I-FLICE-2 polypeptide of the invention or an agonist thereof. A still further aspect of the invention is related to a method for treating an individual in need of a decreased level of I-FLICE- 1 or I-FLICE-2 activity in the body comprising, administering to such an individual a composition comprising a therapeutically effective amount of an I-FLICE- 1 or I-FLICE-2 antagonist. Brief Description of the Figures FIG. 1A-1B shows the nucleotide (SEQ ID NO:l) and deduced amino acid (SEQ ID NO:2) sequences of I-FLICE- 1 (HSLAZ11). The protein has 480 amino acid residues and a deduced molecular weight of about 55.3 kDa. FIG. 2 shows the regions of similarity between the amino acid sequences of the I-FLICE- 1, 1-FLICE-2, FLICE (SEQ ID NO:3), and Mch4 (SEQ ID NO:4). Shading (with solid black) indicates residues that match the consensus sequence exactly. FIG. 3 shows an analysis of the I-FLICE-1 amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown. In the "Antigenic Index- Jameson- Wolf graph, amino acid residues about 41 to about 92, about 155 to about 249, about 332 to about 447 in FIG. 1A-1B (SEQ ID NO:2) correspond to the shown highly antigenic regions of the I-FLICE- 1 protein. FIG. 4A-4C shows the nucleotide (SEQ ID NO:5) and deduced amino acid (SEQ ID NO:6) sequences of I-FLICE-2 (HCEBJ50). The protein has 348 amino acid residues and a deduced molecular weight of about 39.2 kDa. FIG. 5 shows an analysis of the I-FLICE-2 amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown. In the "Antigenic Index - Jameson- Wolf ' graph, amino acid residues about 62 to about 136, about 184 to about 193, about 205 to about 341 in FIG. 4A-4C (SEQ ID NO:6) correspond to the shown highly antigenic regions of the I-FLICE-2 protein. FIG. 6A-6B shows I-FLICE- 1 inhibition of apoptosis. Overexpression of I-FLICE- 1 attenuated TNFR- 1 (panel A) and CD-95 (panel B) induced cell death. 293 (panel A) or 293-EBNA (panel B) cells were co-transfected with the indicated plasmids together with the reporter construct pCMV β-galactosidase. The data shown are the percentage of blebbing blue cells as a function of total number of blue cells counted. Detailed Description The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding an I-FLICE- 1 or I-FLICE-2 polypeptide having the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:6, respectively, which was determined by sequencing a cloned cDNA. The I-FLICE- 1 protein of the present invention shares sequence homology with FLICE and Mch4 (FIG. 2) (SEQ ID NOs:3 and 4). The nucleotide sequence shown in SEQ ID NO:l was obtained by sequencing a cDNA clone (HSLAZ11), which was deposited on May 15, 1997 at the American Type Culture Collection, 12301 Park Lawn Drive, Rockville, Maryland 20852, and given accession number 209038. The deposited clone is inserted in the pBluescript SK(-) plasmid (Stratagene, La Jolla, CA) using the EcoRI and Xhol restriction endonuclease cleavage sites. The I-FLICE-2 protein of the present invention shares sequence homology with FLICE and Mch4 (FIG. 2 (SEQ ID NOs:3 and 4)). The nucleotide sequence shown in SEQ ID NO:5 was obtained by sequencing a cDNA clone (HCEBJ50), which was deposited on May 15, 1997 at the American Type Culture Collection, 12301 Park Lawn Drive, Rockville, Maryland 20852, and given accession number 209041. The deposited clone is inserted in the pBluescript SK(-) plasmid (Stratagene, La Jolla, CA) using the EcoRI and Xhol restriction endonuclease cleavage sites. Nucleic Acid Molecules Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion. Using the information provided herein, such as the nucleotide sequence in SEQ ID NO:l or SEQ ID NO:5, a nucleic acid molecule of the present invention encoding an I-FLICE- 1 or I-FLICE-2 polypeptide may be obtained using standard cloning and screening procedures, such as those for cloning cDNAs using mRNA as starting material. Illustrative of the invention, the nucleic acid molecule described in SEQ ID NO:l was discovered in a cDNA library derived from human umbilical vein endothelial cell. The gene was also identified in cDNA libraries from smooth muscle. The determined nucleotide sequence of the I-FLICE- 1 cDNA of SEQ ID NO:l contains an open reading frame encoding a protein of about 480 amino acid residues and a deduced molecular weight of about 55.3 kDa. The I-FLICE-1 protein shown in SEQ ID NO:2 is overall about 29% identical and about 54% similar to FLICE (FIG. 2 (SEQ ID NO:3)). Also illustrative of the invention, the nucleic acid molecule described in SEQ ID NO: 5 was discovered in a cDNA library derived from human umbilical vein endothelial cell. The gene was also identified in cDNA libraries from brain tissue isolated from the cerebellum. The determined nucleotide sequence of the I-FLICE-2 cDNA of SEQ ID NO:5 contains an open reading frame encoding a protein of about 348 amino acid residues and a deduced molecular weight of about 39 kDa. The I-FLICE-2 protein shown in SEQ ID NO:6 is overall about 28% identical and about 54% similar to FLICE (FIG. 2 (SEQ ID NO:3)). In addition, I-FLICE- 1 and I-FLICE-2 are nearly identical over the majority of their sequences; however, I-FLICE- 1 has additional amino acids comprising the N-terminal region of the protein. The amino terminal domains of both I-FLICE- 1 and I-FLICE-2 exhibit significant sequence similarity to the DED domain of the FADD protein (Hu, S. et al., J. Biol. Chem. 272:17255-17257 (1997); Irmler, M., et al., Nature 555:190-195 (1997)), the domain through which FLICE proteins and death receptors interact. The amino terminal domain of I- FLICE-2 consists of only a single DED/FADD homology domain (comprising amino acid residues from about 1 to about 75 in SEQ ID NO: 6), while the additional amino acids found in the amino terminal domain of I-FLICE- 1 appear to provide a second DED/FADD homology domain (comprising amino acid residues from about 1 to about 75 and amino acids residues from about 91 to about 171 in SEQ ID NO:2). The carboxy terminal domains of the both I-FLICE- 1 and I-FLICE-2 also contain significant sequence similarity to the active subunit domains of the ICE/CED-3 family of cysteine proteases (amino acids residues from about 172 to about 375 and amino acid residues from about 376 to about 480 in SEQ ID NO:2; amino acids residues from about 76 to about 252 and amino acid residues from about 253 to about 348 in SEQ ID NO:6). Neither I- FLICE- 1 or I-FLICE-2 contain the catalytic cysteine that is normally embedded in the conserved pentapeptide QACRG or QACQG motif present in all known caspases. Rather, both I-FLICE- 1 and I-FLICE-2 have the pentapeptide sequence QNYVV (amino acid residues from about 358 to about 362 in SEQ ID NO:2 and amino acid residues from about 244 to about 248 in SEQ ID NO:6). Further, only three of seven conserved residues that form the substrate binding pocket found in all caspases are present in I-FLICE- 1 and I-FLICE-2. Given the lack of conservation of key residues involved in catalysis and substrate binding, it can be concluded that I-FLICE- 1 and I-FLICE-2 are not cysteine proteases and are incapable of substrate binding, thus, providing these proteins with a dominant negative inhibitory function. I-FLICE- 1 and I-FLICE-2 are the first examples of catalytically inert caspases that can inhibit apoptosis. As indicated, nucleic acid molecules of the present invention may be in the form of R A, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand. By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the puφoses of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically. Isolated nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) shown in SEQ ID NO:l or EQ ID NO: 5; DNA molecules comprising the coding sequence for the I-FLICE -1 or I-FLICE-2 protein; and DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the I-FLICE- 1 or I-FLICE-2 protein. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate variants. In addition, the invention provides nucleic acid molecules having nucleotide sequences related to extensive portions of SEQ ID NO:l which have been determined from the following related cDNA clones: HOSBY07R (SEQ ID NO:23), HSAVA13R (SEQ ID NO:24), HLFBD88R (SEQ ID NO:25), HOSAH65R (SEQ ID NO:26), HUVBS23R (SEQ ID NO:27), HHFFJ01RA (SEQ ID NO:28), HUVBL22R (SEQ ID NO:29), and HUVBX15R (SEQ ID NO:30). The invention also provides nucleic acid molecules having nucleotide sequences related to extensive portions of SEQ ID NO: 5 (I-FLICE-2) which have been determined from the following related cDNA clones: HTNBE58R (SEQ ID NO:31), HTPBE58R (SEQ ID NO:32), HOSBY07R (SEQ ID NO:23), HSAVA13R (SEQ ID NO:24), HLFBD88R (SEQ ID NO:25), HOSAH65R (SEQ ID NO:26), and HHFFJ01RA (SEQ ID NO:28). In another aspect, the invention provides isolated nucleic acid molecules encoding the I-FLICE- 1 polypeptide having an amino acid sequence as encoded by the cDNA clone contained in the plasmid deposited as ATCC Deposit No. 209038 on May 15, 1997. The invention also provides isolated nucleic acid molecules encoding the I-FLICE-2 polypeptide having an amino acid sequence as encoded by the cDNA clone contained in the plasmid deposited as ATCC Deposit No. 209041 on May 15, 1997. In a further embodiment, nucleic acid molecules are provided encoding the I-FLICE- 1 or I-FLICE-2 polypeptide or the full-length I-FLICE polypeptide lacking the N-terminal methionine. The invention also provides an isolated nucleic acid molecule having the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 5 or the nucleotide sequence of the I-FLICE- 1 or I-FLICE-2 cDNA contained in the above-described deposited clones, or a nucleic acid molecule having a sequence complementary to one of the above sequences. Such isolated molecules, particularly DNA molecules, are useful as probes for gene mapping, by in situ hybridization with chromosomes, and for detecting expression of the I-FLICE- 1 or I-FLICE-2 gene in human tissue, for instance, by Northern blot analysis. The present invention is further directed to fragments of the isolated nucleic acid molecules described herein. By a fragment of an isolated nucleic acid molecule having the nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in SEQ ID NO:l or SEQ ID NO: 5 is intended fragments at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length which are useful as diagnostic probes and primers as discussed herein. Of course larger DNA fragments 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, or 2016 nt in length of the sequence shown in SEQ ID NO:l are also useful according to the present invention as are fragments corresponding to most, if not all, of the nucleotide sequence of the cDNA clone contained in the plasmid deposited as ATCC Deposit No.209038 or as shown in SEQ ID NO: 1. Similarly, larger DNA fragments 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, or 2547 nt in length of the sequence shown in SEQ ID NO: 5 are also useful according to the present invention as are fragments corresponding to most, if not all, of the nucleotide sequence of the cDNA clone contained in the plasmid deposited as ATCC Deposit No. 209041 or as shown in SEQ ID NO:5. By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases from the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in SEQ ID NO:l or SEQ ID NO:5. In a more specific embodiment, the nucleic acid molecules of the present invention do not include the sequences, nucleic acid molecules (e.g., clones), or nucleic acid inserts identified in one or more of the following GenBank Accession Reports: AA001257, AA151642, AA149562, C05730, AA565691, AA467756, D83882, AA002262, AA115793, AA467995, AA115792, AA467938, W60406, AA358042, AA468056, W23795, AA358043, T93307, AA453850, AA379905, AA296229, HI 5978, AA501289, AA296309, AA296174, T30922, T48754, AA453766, C05795, AA198928, N94588, H15052, Z42895, F13176, W52946, AA558404, AA070614, AA613966, AA525331, AA663074, AA135811, AA526099, AA302978, H68343, AA610255, AA229005, T05118, T30864, AA302968, or AA364006, all of which are incoφorated herein by reference. Preferred nucleic acid fragments of the present invention include nucleic acid molecules encoding epitope-bearing portions of the I-FLICE- 1 protein. In particular, such nucleic acid fragments of the present invention include nucleic acid molecules encoding: a polypeptide comprising amino acid residues from about 41 to about 92 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 155 to about 249 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 332 to about 474 in SEQ ID NO:2. The inventors have determined that the above polypeptide fragments are antigenic regions of the I-FLICE- 1 protein. Methods for determining other such epitope-bearing portions of the I-FLICE- 1 protein are described in detail below. Preferred nucleic acid fragments of the present invention include nucleic acid molecules encoding epitope-bearing portions of the I-FLICE-2 protein. In particular, such nucleic acid fragments of the present invention include nucleic acid molecules encoding: a polypeptide comprising amino acid residues from about 62 to about 136 in SEQ ID NO:6; a polypeptide comprising amino acid residues from about 184 to about 193 in SEQ ID NO:6; a polypeptide comprising amino acid residues from about 205 to about 341 in SEQ ID NO:6. The inventors have determined that the above polypeptide fragments are antigenic regions of the I-FLICE-2 protein. Methods for determining other such epitope-bearing portions of the I-FLICE-2 protein are described in detail below. In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a portion of the polynucleotide in a nucleic acid molecule of the invention described above, for instance, the cDNA clones contained in ATCC Deposit 209038 or ATCC Deposit 209041. By "stringent hybridization conditions" is intended overnight incubation at 42 °C in a solution comprising: 50% formamide, 5x SSC (150 mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C. By a polynucleotide which hybridizes to a "portion" of a polynucleotide is intended a polynucleotide (either DNA or RNA) hybridizing to at least about 15 nucleotides (nt), and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably about 30-70 nt of the reference polynucleotide. These are useful as diagnostic probes and primers as discussed above and in more detail below. By a portion of a polynucleotide of "at least 20 nt in length," for example, is intended 20 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide (e.g., the deposited cDNAs or the nucleotide sequence as shown in SEQ ID NO:l or SEQ ID NO:5). Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3' terminal poly(A) tract of the I-FLICE- 1 cDNA shown in SEQ ID NO: 1 or the I- FLICE-2 cDNA shown in SEQ ID NO:5), or to a complementary stretch of T (or U) resides, would not be included in a polynucleotide of the invention used to hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone). As indicated, nucleic acid molecules of the present invention which encode an I-FLICE- 1 or I-FLICE-2 polypeptide may include, but are not limited to those encoding the amino acid sequence of the polypeptide, by itself; the coding sequence for the mature polypeptide and additional sequences, such as those encoding a secretory sequence, such as a pre-, or pro- or prepro- protein sequence; the coding sequence of the polypeptide, with or without the aforementioned additional coding sequences, together with additional, non-coding sequences, including for example, but not limited to introns and non-coding 5 ' and 3 ' sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals, for example - ribosome binding and stability of mRNA; an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities. Thus, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in Gentz et al, Proc. Natl. Acad. Sci. USA 5(5:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. The "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson et al, Cell 57:767- 778 (1984). As discussed below, other such fusion proteins include the I-FLICE- 1 or I-FLICE-2 fused to Fc at the N- or C-terminus. The present invention further relates to variants of the nucleic acid molecules of the present invention, which encode portions, analogs or derivatives of the I-FLICE- 1 or I-FLICE-2 protein. Variants may occur naturally, such as a natural allelic variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985). Non-naturally occurring variants may be produced using art-known mutagenesis techniques. Such variants include those produced by nucleotide substitutions, deletions or additions, which may involve one or more nucleotides. The variants may be altered in coding regions, non-coding regions, or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the I-FLICE- 1 or I-FLICE-2 protein or portions thereof. Also especially preferred in this regard are conservative substitutions. Further embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 95%), 96%), 97%), 98%) or 99% identical to (a) a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:2; (b) a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:2, but lacking the N-terminal methionine; (c) a nucleotide sequence encoding the polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209038; or (d) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), or (c). Further embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 95%), 96%o, 97%), 98%> or 99%> identical to (a) a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:6; (b) a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO: 6, but lacking the N-terminal methionine; (c) a nucleotide sequence encoding the polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209041; or (d) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), or (c). Additional embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 95%), 96%>, 97%>, 98%) or 99% identical to (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 75 in SEQ ID NO:2; (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 91 to about 171 in SEQ ID NO:2; (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 172 to about 375 in SEQ ID NO:2; (d) a nucleotide sequence encoding a polypeptide comprising amino acids from about 376 to about 480 in SEQ ID NO:2; (e) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 75 in SEQ ID NO:6; (f) a nucleotide sequence encoding a polypeptide comprising amino acids from about 76 to about 252 in SEQ ID NO:6; (g) a nucleotide sequence encoding a polypeptide comprising amino acids from about 253 to about 348 in SEQ ID NO:6; (h) or a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), or (g). By a polynucleotide having a nucleotide sequence at least, for example, 95%o "identical" to a reference nucleotide sequence encoding an I-FLICE polypeptide is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding an I-FLICE polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95%> identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5%> of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 ' or 3 ' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular nucleic acid molecule is at least 95%, 96%, 97%, 98% or 99% identical to, for instance, the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 5 or to the nucleotides sequence of the deposited cDNA clone can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). Bestfit uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981), to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95%> identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5%> of the total number of nucleotides in the reference sequence are allowed. The present application is directed to nucleic acid molecules at least 95%>, 96%, 97%, 98% or 99%> identical to the nucleic acid sequence shown in SEQ ID NO:l or SEQ ID NO:5 or to the nucleic acid sequence of the deposited cDNAs, irrespective of whether they encode a polypeptide having I-FLICE activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having I-FLICE activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having I-FLICE activity include, inter alia, (1) isolating the I-FLICE- 1 or I-FLICE-2 gene or allelic variants thereof in a cDNA library; (2) in situ hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the I-FLICE- 1 or I-FLICE-2 gene, as described in Verma et al, Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York (1988); and (3) Northern Blot analysis for detecting I-FLICE- 1 or I-FLICE-2 mRNA expression in specific tissues. Preferred, however, are nucleic acid molecules having sequences at least 95%, 96%o, 97%, 98%) or 99%> identical to a nucleic acid sequence shown in SEQ ID NO:l or SEQ ID NO: 5 or to a nucleic acid sequence of the deposited cDNA which do, in fact, encode a polypeptide having I-FLICE protein activity. By "a polypeptide having I-FLICE activity" is intended polypeptides exhibiting I- FLICE-1 or I-FLICE-2 activity in a particular biological assay. For example, I- FLICE-1 or I-FLICE-2 protein activity can be measured using the cell death assay as described in Example 6. Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 95%>, 96%>, 97%>, 98%>, or 99%) identical to a nucleic acid sequence of the deposited cDNA or a nucleic acid sequence shown in SEQ ID NO:l or SEQ ID NO:5 will encode "a polypeptide having I-FLICE activity." In fact, since degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having I-FLICE activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid). For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science 2-^7. 1306-1310 (1990), wherein the authors indicate that proteins are suφrisingly tolerant of amino acid substitutions. Vectors and Host Cells The present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of I-FLICE- 1 or I- FLICE-2 polypeptides or fragments thereof by recombinant techniques. The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells. The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp and tac promoters, the SV40 early and late promoters and promoters of retro viral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated. As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art. Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNHlόa, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXTl and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al, Basic Methods In Molecular Biology (1986). The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize proteins. For example, EP-A-O 464 533 (Canadian counteφart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232262). On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the advantageous manner described. This is the case when Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as antigen for immunizations. In drug discovery, for example, human proteins, such as, hIL5 -receptor has been fused with Fc portions for the puφose of high-throughput screening assays to identify antagonists of hIL-5. See, D. Bennett et al, Journal of Molecular Recognition, Vol. 8:52-58 (1995) and K. Johanson et al, The Journal of Biological Chemistry, Vol. 270, No. 16:9459-9471 (1995). The I-FLICE- 1 or I-FLICE-2 protein can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. I-FLICE-1 andI-FLICE-2 Polypeptides and Fragments The invention further provides an isolated I-FLICE- 1 or I-FLICE-2 polypeptide having the amino acid sequence encoded by the deposited cDNAs, or the amino acid sequence in SEQ ID NO:2 or SEQ ID NO:6, or a peptide or polypeptide comprising a portion of the above polypeptides. It will be recognized in the art that some amino acid sequences of the I- FLICE-1 or I-FLICE-2 polypeptide can be varied without significant effect of the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity. Thus, the invention further includes variations of the I-FLICE- 1 or I- FLICE-2 polypeptide which show substantial I-FLICE- 1 or I-FLICE-2 polypeptide activity or which include regions of I-FLICE- 1 or I-FLICE-2 protein such as the protein portions discussed below. Such mutants include deletions, insertions, inversions, repeats, and type substitutions. As indicated above, guidance concerning which amino acid changes are likely to be phenotypically silent can be found in Bowie, J.U., et al, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science 247. 1306-1310 (1990). Thus, the fragment, derivative or analog of the polypeptide of SEQ ID NO:2 or SEQ ID NO:6, or that encoded by the deposited cDNAs, may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein. Of particular interest are substitutions of charged amino acids with another charged amino acid and with neutral or negatively charged amino acids. The latter results in proteins with reduced positive charge to improve the characteristics of the I-FLICE- 1 or I-FLICE-2 protein. The prevention of aggregation is highly desirable. Aggregation of proteins not only results in a loss of activity but can also be problematic when preparing pharmaceutical formulations, because they can be immunogenic. (Pinckard et al, Clin. Exp. Immunol 2:331-340 (1967); Robbins etal, Diabetes 5(5:838-845 (1987); Cleland et al. Crit. Rev. Therapeutic Drug Carrier Systems 70:307-377 (1993)). The replacement of amino acids can also change the selectivity of binding to cell surface receptors. Ostade et al, Nature 5(57:266-268 (1993) describes certain mutations resulting in selective binding of TNF-α to only one of the two known types of TNF receptors. Thus, the I-FLICE- 1 or I-FLICE-2 of the present invention may include one or more amino acid substitutions, deletions or additions, either from natural mutations or human manipulation. As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 1). TABLE 1. Conservative Amino Acid Substitutions. Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above and below. Generally speaking, the number of substitutions for any given I-FLICE- 1 or I-FLICE-2 polypeptide, or mutant thereof, will not be more than 50, 40, 30, 20, 10, 5, or 3, depending on the objective. Amino acids in the I-FLICE- 1 or I-FLICE-2 protein of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. Sites that are critical for ligand interactions can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al, J. Mol Biol. 224:899-904 (1992) and de Vos et al. Science 255:306-312 (1992)). The polypeptides of the present invention are preferably provided in an isolated form. By "isolated polypeptide" is intended a polypeptide removed from its native environment. Thus, a polypeptide produced and/or contained within a recombinant host cell is considered isolated for puφoses of the present invention. Also intended as an "isolated polypeptide" are polypeptides that have been purified, partially or substantially, from a recombinant host cell. For example, a recombinantly produced version of the I-FLICE- 1 or I-FLICE-2 polypeptide can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). The polypeptides of the present invention include the polypeptide encoded by the deposited cDNA; a polypeptide comprising amino acids about 1 to about 480 in SEQ ID NO:2; a polypeptide comprising amino acids about 2 to about 480 in SEQ ID NO:2; as well as polypeptides which are at least 95%) identical, still more preferably at least 96%>, 97%>, 98%> or 99%) identical to those described above and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids. The polypeptides of the present invention also include the polypeptide encoded by the deposited cDNA; a polypeptide comprising amino acids about 1 to about 348 in SEQ ID NO:6; a polypeptide comprising amino acids about 2 to about 348 in SEQ ID NO:6; as well as polypeptides which are at least 95% identical, still more preferably at least 96%>, 97%>, 98%> or 99%o identical to those described above and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids. The polypeptides of the present invention further include the polypeptide comprising amino acids from about 1 to about 75 in SEQ ID NO:2; amino acids from about 91 to about 171 in SEQ ID NO:2; amino acids from about 172 to about 375 in SEQ ID NO:2; amino acids from about 376 to about 480 in SEQ ID NO:2; amino acids from about 1 to about 75 in SEQ ID NO:6; amino acids from about 76 to about 252 in SEQ ID NO:6; amino acids from about 253 to about 348 in SEQ ID NO:6; as well as polypeptides which are at least 95%> identical, still more preferably at least 96%, 97%, 98%> or 99%> identical to those described above and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids. By a polypeptide having an amino acid sequence at least, for example, 95%) "identical" to a reference amino acid sequence of an I-FLICE- 1 or I-FLICE-2 polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the I-FLICE- 1 or I-FLICE-2 polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95%> identical to a reference amino acid sequence, up to 5%> of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5%> of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular polypeptide is at least 95%, 96%>, 97%>, 98%> or 99% identical to, for instance, the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:6 or to the amino acid sequence encoded by deposited cDNA clones can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95%o identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5%> of the total number of amino acid residues in the reference sequence are allowed. The polypeptide of the present invention are useful as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. In another aspect, the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention. The epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide described herein. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen et al, Proc. Natl. Acad. Sci. USA 57:3998- 4002 (1983). As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G., Shinnick, T. M., Green, N. and Learner, R.A. (1983) Antibodies that react with predetermined sites on proteins. Science 219:660-666. Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. See, for instance, Wilson et al, Cell 57:767-778 (1984) at 777. Antigenic epitope-bearing peptides and polypeptides of the invention preferably contain a sequence of at least seven, more preferably at least nine and most preferably between about at least about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention. Non-limiting examples of antigenic polypeptides or peptides that can be used to generate I-FLICE- 1 -specific antibodies include: a polypeptide comprising amino acid residues from about 41 to about 92 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 155 to about 249 in SEQ ID NO:2; a polypeptide comprising amino acid residues from about 332 to about 474 in SEQ ID NO:2. As indicated above, the inventors have determined that the above polypeptide fragments are antigenic regions of the I-FLICE- 1 protein. Non-limiting examples of antigenic polypeptides or peptides that can be used to generate I-FLICE-2 -specific antibodies include: a polypeptide comprising amino acid residues from about 62 to about 136 in SEQ ID NO:6; a polypeptide comprising amino acid residues from about 184 to about 193 in SEQ ID NO:6; a polypeptide comprising amino acid residues from about 205 to about 341 in SEQ ID NO:6. The inventors have determined that the above polypeptide fragments are antigenic regions of the I-FLICE-2 protein. The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means. Houghten, R. A. (1985) General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. USA 52:5131-5135. This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten et al. (1986). As one of skill in the art will appreciate, I-FLICE- 1 or I-FLICE-2 polypeptides of the present invention and the epitope-bearing fragments thereof described above can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. This has been shown, e.g., for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins (EPA 394,827; Traunecker et al, Nature 557:84- 86 (1988)). Fusion proteins that have a disulfide-linked dimeric structure due to the IgG part can also be more efficient in binding and neutralizing other molecules than the monomeric I-FLICE- 1 or I-FLICE-2 protein or protein fragment alone (Fountoulakis et al, J. Biochem 270:3958-3964 (1995)). Disease Diagnosis and Prognosis It is believed that certain tissues in mammals with specific disease states associated with aberrant cell survival express significantly altered levels of I-FLICE- 1 or I-FLICE-2 and mRNA encoding I-FLICE- 1 or I-FLICE-2 when compared to a corresponding "standard" mammal, i.e., a mammal of the same species not having the disease state. Thus, the present invention is useful for detecting such states in mammals. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans. It is further believed that enhanced levels of I-FLICE- 1 or I-FLICE-2 can be detected in certain body fluids (e.g., sera, plasma, urine, and spinal fluid) from mammals with the disease state when compared to analogous fluids from mammals of the same species not having the disease state. Thus, the invention provides a diagnostic method useful during diagnosis of disease states, which involves assaying the expression level of the gene encoding I-FLICE- 1 or I-FLICE-2 in mammalian cells or body fluid and comparing the gene expression level with a standard I-FLICE- 1 or I-FLICE-2, whereby an increase or decrease in the gene expression level over the standard is indicative of certain disease states associated with aberrant cell survival. Where diagnosis of a disease state involving I-FLICE- 1 or I-FLICE-2 of the present invention has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting significantly aberrant I-FLICE- 1 or I-FLICE-2 gene expression levels will experience a worse clinical outcome relative to patients expressing the gene at a lower level. By "assaying the expression level of the gene encoding I-FLICE-1 or I-FLICE-2" is intended qualitatively or quantitatively measuring or estimating the level of I-FLICE- 1 or I-FLICE-2 protein or the level of the mRNA encoding I-FLICE-1 or I-FLICE-2 protein in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the I-FLICE-1 or I-FLICE-2 protein level or mRNA level in a second biological sample). Preferably, the I-FLICE- 1 or I-FLICE-2 protein level or mRNA level in the first biological sample is measured or estimated and compared to a standard I-FLICE- 1 or I-FLICE-2 protein level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disease state. As will be appreciated in the art, once a standard I-FLICE- 1 or I-FLICE-2 protein level or mRNA level is known, it can be used repeatedly as a standard for comparison. By "biological sample" is intended any biological sample obtained from an individual, cell line, tissue culture, or other source which contains I-FLICE- 1 or I-FLICE-2 protein or mRNA. Biological samples include mammalian body fluids (such as sera, plasma, urine, synovial fluid and spinal fluid) which contain I-FLICE- 1 or I-FLICE-2 protein, and ovarian, prostate, heart, placenta, pancreas liver, spleen, lung, breast, umbilical tissue, and other tissues. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source. Diseases associated with increased cell survival, or the inhibition of apoptosis, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, hormone-dependent tumors, and cancers of the breast, ovary, prostate, bone, liver, lung, pancreas, and spleen); autoimmune disorders (such as systemic lupus erythematosus and immune-related glomerulonephritis rheumatoid arthritis) and viral infections (such as heφes viruses, pox viruses and adenoviruses), information graft v. host disease, acute graft rejection, and chronic graft rejection. Diseases associated with decreased cell survival, or increased apoptosis, include Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock, sepsis, stroke, CNS inflammation, osteoporosis, ischemia, reperfusion injury, cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis of endothelial cells in cardiovascular disease, degenerative liver disease, MS and head injury damage. Assays available to detect levels of proteins are well known to those of skill in the art, for example, radioimmunoassays, competitive-binding assays, Western blot analysis, and preferably an ELISA assay may be employed. I-FLICE- 1 or I-FLICE-2 specific antibodies can be raised against the intact I-FLICE- 1 or I-FLICE-2 protein or an antigenic polypeptide fragment thereof, which may presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. As used herein, the term "antibody" (Ab) or "monoclonal antibody" (mAb) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab') 2 fragments) which are capable of specifically binding to the I-FLICE- 1 or I-FLICE-2 protein. Fab and F(ab') 2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al, J. Nucl. Med. 24:316-325 (1983)). Thus, these fragments are preferred. The antibodies of the present invention may be prepared by any of a variety of methods. For example, cells expressing the I-FLICE- 1 or I-FLICE-2 protein or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of I-FLICE- 1 or I-FLICE-2 protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity. In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or I-FLICE- 1 or I-FLICE-2 protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology (Kohler et al, Nature 25(5:495 (1975); Kohler et al, Eur. J. Immunol. 6:5\ \ (1976); Kohler et al, Eur. J. Immunol. 6:292 (1976); Hammerling et al, In: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., (1981) pp. 563-681). Assaying I-FLICE- 1 or I-FLICE-2 protein levels in a biological sample can occur using antibody-based techniques. For example, I-FLICE- 1 or l-FLICE- 2 protein expression in tissues can be studied with classical immunohistological methods (Jalkanen, M., et al, J. Cell. Biol. 707:976-985 (1985); Jalkanen, M., et al, J. Cell . Biol. 705.3087-3096 (1987)). As noted above, other antibody-based methods useful for detecting I- FLICE- 1 or I-FLICE-2 protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable labels are known in the art and include enzyme labels, such as, Glucose oxidase, and radioisotopes, such as iodine ( 125 1, 121 I), carbon ( 14 C), sulfur ( 35 S), tritium ( 3 H), indium (' 12 In), and technetium ( 99m Tc), and fluorescent labels, such as fluorescein and rhodamine, and biotin. Total cellular RNA can be isolated from a biological sample using the single-step guanidinium-thiocyanate-phenol-chloroform method described in C omczynski and Sacc i, Anal. Biochem. 7(52. 156-159 (1987). Levels of mRNA encoding the I-FLICE- 1 or I-FLICE-2 protein are then assayed using any appropriate method. These include Northern blot analysis (Harada et al, Cell (55:303-312 (1990)), SI nuclease mapping (Fujita et al, Cell 49:357- 367 (1987)), the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR) (Makino et al, Technique 2:295-301 (1990)), and reverse transcription in combination with the ligase chain reaction (RT-LCR). Agonists and Antagonists -Assays and Molecules The invention also provides a method of screening compounds to identify agonists and antagonists of I-FLICE- 1 or I-FLICE-2. By "agonist" is intended naturally occurring and synthetic compounds capable of enhancing one or more activity mediated by I-FLICE- 1 or I-FLICE-2 polypeptides. By "antagonist" is intended naturally occurring and synthetic compounds capable of inhibiting one or more activity mediated by I-FLICE- 1 or I-FLICE-2 polypeptides. Thus, in a further aspect, a screening method is provided for determining whether a candidate agonist or antagonist is capable of enhancing or inhibiting a cellular activity of either an I-FLICE- 1 or I-FLICE-2 polypeptide. The method involves contacting cells which express one or both of the I-FLICE- 1 or I-FLICE- 2 polypeptides with a candidate compound, assaying a cellular response, and comparing the cellular response to a standard cellular response, the standard being assayed in absence of the candidate compound, whereby an increased cellular response over the standard indicates that the candidate compound is an agonist of the polypeptide activity and a decreased cellular response compared to the standard indicates that the candidate compound is an antagonist of the activity. By "assaying a cellular response" is intended qualitatively or quantitatively measuring a cellular response in the presence of a candidate compound and either an I-FLICE- 1 or I-FLICE-2 polypeptide (e.g., decreased or increased TNFR-1 or CD-95 induced apoptosis, binding of I-FLICE- 1 or I-FLICE-2 to natural cellular ligands such as FLICE and Mch4/FLICE2). Potential antagonists include small organic molecules amino acid sequences which bind to I-FLICE- 1 or I-FLICE-2, fragments of I-FLICE- 1 and I-FLICE-2, as well as anti-I-FLICE-1 and anti-I-FLICE-2 antibodies. Fragments of I-FLICE- 1 and I-FLICE-2, which may be naturally occurring or synthetic, antagonize I-FLICE- 1 and I-FLICE-2 polypeptide mediated activities by competing for binding to natural cellular ligands. Small organic molecules can antagonize I-FLICE- 1 and I-FLICE-2 polypeptide mediated activities by binding either competitively or non-competitively to I-FLICE- 1 or I-FLICE-2 or a cellular ligand of these proteins. Examples of small molecules include but are not limited to nucleotide sequences and small peptides or peptide-like molecules. Such molecules may be produced and screened for activity by a variety of methods (e.g., Light and Lerner, Bioorganic & Medicinal Chemistry 3(7):955-967 (1995); Cheng et al, Gene 777:1-8 (1996); Gates et al, J. Mol Biol. 255:373-386 (1996)). Similarly, potential agonists also include fragments of the polypeptides of the present invention, as well as anti-I-FLICE-1 and anti-I-FLICE-2 antibodies. Fragments of these proteins can act as agonists of I-FLICE- 1 and I-FLICE-2 polypeptide mediated activities by binding to natural cellular ligands and inducing activities associated with the full-length protein. Agonists and antagonists of the present invention also include amino acid sequences having 95%> or more identity to those shown in SEQ ID NOs:2 and 6, or fragments thereof. Other potential antagonists include antisense oligonucleotides and oligonucleotides capable of forming triple helices with the sequences shown in SEQ ID NOs: 1 and 5. Once a gene sequence is known, antisense and triple helix technologies can be used to regulate gene expression. Okano, J. Neurochem. 56:560 (1991); OLIGONUCLEOTIDES AS INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, FL. (1988); Dervan et al, Science 257:1360 (1991); Cooney et al, Science 247:456 (1988); Lee et al, Nucl. Acids Res. -5:3073 (1979). In regards to antisense technology, for example, an oligonucleotide may be designed which is complementary to a portion of the I-FLICE- 1 or I-FLICE-2 DNA sequences which is transcribed into RNA. This oligonucleotide may be delivered to cells in a number of forms, including as antisense RNA or incoφorated into an expression vector. If incoφorated into an expression vector, the oligonucleotide is generally orientated in a manner that an RNA molecule is produced upon in vivo expression which is complementary to that of the I-FLICE- 1 or I-FLICE-2 mRNA sequence. The expressed antisense RNA molecule will hybridize to I- FLICE-1 or I-FLICE-2 mRNA and block translation in vivo. The experiments set forth in Example 5 demonstrate that I-FLICE- 1 binds to both FLICE and Mch4/FLICE2. Immunprecipitation assays similar to that described in Example 5 can be used to identify additional molecules which bind to I-FLICE- 1 and I-FLICE-2. Such binding molecules are candidate antagonists and agonists. Example 6 sets forth a cell death assay used to demonstrate that overexpression of I-FLICE- 1 results in the inhibition of TNFR-1 and CD-95 induced cell death. This assay can also be used to screen for compounds having agonistic and antagonistic activity directed to I-FLICE- 1 and I-FLICE-2. Such a screening method is used to determine whether the compound increases or decreases TNFR-1 and CD-95 induced cell death in the presence of I-FLICE- 1 or I-FLICE-2 either individually or in combination. Proteins and other compounds which bind the I-FLICE- 1 or I-FLICE-2 polypeptide domains are also candidate agonists and antagonists according to the present invention. Such binding compounds can be "captured" using the yeast two-hybrid system (Fields and Song, Nature 340:245-246 (1989); Gyuris et al, Cell 75:791-803 (1993); Zervos et al, Cell 72:223 -232 (1993)). The agonists may be employed for instance to enhance the action of I- FLICE-1 or I-FLICE-2 polypeptides, for example, in the treatment of Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock, sepsis, stroke, CNS inflammation, osteoporosis, ischemia, reperfusion injury, cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis of endothelial cells in cardiovascular disease, degenerative liver disease, MS and head injury damage. The antagonists may be employed for instance to inhibit the action of I- FLICE-1 or I-FLICE-2 polypeptides, for example, in the treatment of cancers (such as follicular lymphomas, carcinomas with p53 mutations, hormone- dependent tumors, and cancers of the breast, ovary, prostate, bone, liver, lung, pancreas, and spleen); autoimmune disorders (such as systemic lupus erythematosus and immune-related glomerulonephritis rheumatoid arthritis) and viral infections (such as heφes viruses, pox viruses and adenoviruses), information graft v. host disease, acute graft rejection, and chronic graft rejection. The agonists and antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as hereinafter described. Therapeutics The novel mammalian inhibitors designated I-FLICE- 1 and I-FLICE-2 (for inhibitor of FLICE of the present invention, are catalytically inactive structural homologues of FLICE and Mch4/FLICE2 that inhibit both TNFR-1 and CD-95 induced apoptosis. These are the first examples of a naturally occurring catalytically inactive caspase that can act as a dominant negative inhibitor of apoptosis. The polypeptides of the present invention are useful for inhibiting apoptosis for therapeutic puφoses, for example, in the treatment of Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock, sepsis, stroke, CNS inflammation, osteoporosis, ischemia, reperfusion injury, cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis of endothelial cells in cardiovascular disease, degenerative liver disease, MS and head injury damage. Modes of Administration It will be appreciated that conditions caused by a decrease in the standard or normal level of I-FLICE- 1 or I-FLICE-2 activity in an individual, can be treated by administration of I-FLICE- 1 or I-FLICE-2 protein. Thus, the invention further provides a method of treating an individual in need of an increased level of I-FLICE- 1 or I-FLICE-2 activity comprising administering to such an individual a pharmaceutical composition comprising an effective amount of an isolated I-FLICE- 1 or I-FLICE-2 polypeptide of the invention, particularly a mature form of the I-FLICE- 1 or I-FLICE-2, effective to increase the I-FLICE- 1 or I-FLICE-2 activity level in such an individual. As a general proposition, the total pharmaceutically effective amount of I-FLICE- 1 or I-FLICE-2 polypeptide administered parenterally per dose will be in the range of about 1 μg/kg/day to 10 mg kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the I-FLICE- 1 or I-FLICE-2 polypeptide is typically administered at a dose rate of about 1 μg/kg hour to about 50 μg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. Pharmaceutical compositions containing the I-FLICE- 1 or I-FLICE-2 of the invention may be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), bucally, or as an oral or nasal spray. By "pharmaceutically acceptable carrier" is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. Chromosome Assays The nucleic acid molecules of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease. In certain preferred embodiments in this regard, the cDNA herein disclosed is used to clone genomic DNA of an I-FLICE- 1 or I-FLICE-2 protein gene. This can be accomplished using a variety of well known techniques and libraries, which generally are available commercially. The genomic DNA then is used for in situ chromosome mapping using well known techniques for this puφose. In addition, in some cases, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the 3' untranslated region of the gene is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Fluorescence in situ hybridization ("FISH") of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with probes from the cDNA as short as 50 or 60 bp. For a review of this technique, see Verma et al, Human Chromosomes: A Manual Of Basic Techniques, Pergamon Press, New York (1988). Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance In Man, available on-line through Johns Hopkins University, Welch Medical Library. The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease. Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting. Examples Example 1(a): Expression and Purification ofl-FLICE-l in E. coli The bacterial expression vector pQE60 is used for bacterial expression in this example. (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311). pQE60 encodes ampicillin antibiotic resistance ("Amp r ") and contains a bacterial origin of replication ("ori"), an IPTG inducible promoter, a ribosome binding site ("RBS"), six codons encoding histidine residues that allow affinity purification using nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin sold by QIAGEN, Inc., supra, and suitable single restriction enzyme cleavage sites. These elements are arranged such that an inserted DNA fragment encoding a polypeptide expresses that polypeptide with the six His residues (i.e., a "6 X His tag") covalently linked to the carboxyl terminus of that polypeptide. The DNA sequence encoding the desired portion I-FLICE- 1 protein is amplified from the deposited cDNA clone using PCR oligonucleotide primers which anneal to the amino terminal sequences of the desired portion of the I- FLICE-1 protein and to sequences in the deposited construct 3' to the cDNA coding sequence. Additional nucleotides containing restriction sites to facilitate cloning in the pQE60 vector are added to the 5' and 3' sequences, respectively. For cloning the protein, the 5' primer has the sequence: 5' CGCCCATGGCTGAAGTCATCCATCAG 3' (SEQ ID NO:7) containing the underlined Ncol restriction site followed by 16 (i.e., 275-291) nucleotides complementary to the amino terminal coding sequence of the I-FLICE- 1 sequence in FIG. 1 A-1B (SEQ ID NO: 1). One of ordinary skill in the art would appreciate, of course, that the point in the protein coding sequence where the 5' primer begins may be varied to amplify a DNA segment encoding any desired portion of the complete protein in a shorter or longer form. The 3' primer has the sequence: 5' CGCAAGCTTGTGCTGGGATTACAGGTG 3' (SEQ IDNO:8) containing the underlined Hindϋl restriction site followed by 18 (i.e., 1740-1758) nucleotides complementary to the 3' end of the coding sequence immediately before the stop codon in the I-FLICE-1 DNA sequence in FIG. 1A-1B (SEQ ID NO:l). with the coding sequence aligned with the restriction site so as to maintain its reading frame with that of the six His codons in the pQE60 vector. The amplified I-FLICE- 1 DNA fragment and the vector pQE60 are digested with Ncol/Hindlll and the digested DNAs are then ligated together. Insertion of the I-FLICE- 1 DNA into the restricted pQE60 vector places the I- FLICE-1 protein coding region downstream from the IPTG-inducible promoter and in-frame with an initiating AUG and the six histidine codons. The ligation mixture is transformed into competent E. coli cells using standard procedures such as those described in Sambrook et al, Molecular Cloning: a laboratory Manual, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989). E. coli strain M15/rep4, containing multiple copies of the plasmid pREP4, which expresses the lac repressor and confers kanamycin resistance ("Kan r "), is used in carrying out the illustrative example described herein. This strain, which is only one of many that are suitable for expressing I-FLICE- 1 protein, is available commercially from QIAGEN, Inc.. supra. Transformants are identified by their ability to grow on LB plates in the presence of ampicillin and kanamycin. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing. Clones containing the desired constructs are grown overnight ("O/N") in liquid culture in LB media supplemented with both ampicillin (100 μg/ml) and kanamycin (25 μg/ml). The O/N culture is used to inoculate a large culture, at a dilution of approximately 1 :25 to 1 :250. The cells are grown to an optical density at 600 nm ("OD600") of between 0.4 and 0.6. Isopropyl-b-D- thiogalactopyranoside ("IPTG") is then added to a final concentration of 1 mM to induce transcription from the lac repressor sensitive promoter, by inactivating the lad repressor. Cells subsequently are incubated further for 3 to 4 hours. Cells then are harvested by centrifugation. The cells are then stirred for 3-4 hours at 4°C in 6M guanidine-HCl, pH 8. The cell debris is removed by centrifugation, and the supernatant containing the I-FLICE- 1 is loaded onto a nickel-nitrilo-tri-acetic acid ("NiNTA") affinity resin column (available from QIAGEN, Inc., supra). Proteins with a 6 x His tag bind to the NI-NTA resin with high affinity and can be purified in a simple one- step procedure (for details see: The QIAexpressionist, 1995, QIAGEN, Inc., supra). Briefly the supernatant is loaded onto the column in 6 M guanidine-HCl, pH8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH8, then washed with 10 volumes of 6 M guanidine-HCl pH6, and finally the I- FLICE-1 is eluted with 6 M guanidine-HCl, pH5. The purified protein is then renatured by dialyzing it against phosphate- buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80 °C. Example 1(b): Expression and Purification ofI-FLICE-2 in E. coli The bacterial expression vector pQE60 is used for bacterial expression in this example. (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311). pQE60 encodes ampicillin antibiotic resistance ("Amp r ") and contains a bacterial origin of replication ("ori"), an IPTG inducible promoter, a ribosome binding site ("RBS"), six codons encoding histidine residues that allow affinity purification using nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin sold by QIAGEN, Inc., supra, and suitable single restriction enzyme cleavage sites. These elements are arranged such that an inserted DNA fragment encoding a polypeptide expresses that polypeptide with the six His residues (i.e., a "6 X His tag") covalently linked to the carboxyl terminus of that polypeptide. The DNA sequence encoding the desired portion I-FLICE-2 protein is amplified from the deposited cDNA clone using PCR oligonucleotide primers which anneal to the amino terminal sequences of the desired portion of the I- FLICE-2 protein and to sequences in the deposited construct 3' to the cDNA coding sequence. Additional nucleotides containing restriction sites to facilitate cloning in the pQE60 vector are added to the 5' and 3' sequences, respectively. For cloning the protein, the 5' primer has the sequence: 5' CGCCCAIGGAGATTGGTGAGGATTTG 3' (SEQ ID NO:9) containing the underlined Ncol restriction site followed by 17 (i.e., 311-328) nucleotides complementary to the amino terminal coding sequence of the I-FLICE-2 sequence in FIG. 4A-4C (SEQ ID NO:5). one of ordinary skill in the art would appreciate, of course, that the point in the protein coding sequence where the 5' primer begins may be varied to amplify a DNA segment encoding any desired portion of the complete protein in a shorter or longer form. The 3' primer has the sequence: 5' CGCAAGCTIAGAGCATGCAGTGTCAG 3' (SEQ ID NO: 10) containing the underlined Hindlll restriction site followed by 16 (i.e., 1400-1416) nucleotides complementary to the 3' end of the coding sequence immediately before the stop codon in the I-FLICE-2 DNA sequence in FIG. 4A-4C (SEQ ID NO:5), with the coding sequence aligned with the restriction site so as to maintain its reading frame with that of the six His codons in the pQE60 vector. The amplified I-FLICE-2 DNA fragment and the vector pQE60 are digested with Ncol/Hindlll and the digested DNAs are then ligated together. Insertion of the I-FLICE-2 DNA into the restricted pQE60 vector places the I- FLICE-2 protein coding region downstream from the IPTG-inducible promoter and in-frame with an initiating AUG and the six histidine codons. The ligation mixture is transformed into competent E. coli cells using standard procedures such as those described in Sambrook et al, Molecular Cloning: a laboratory Manual, 2nd Ed; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989). E. coli strain M15/rep4, containing multiple copies of the plasmid pREP4, which expresses the lac repressor and confers kanamycin resistance ("Kan r "), is used in carrying out the illustrative example described herein. This strain, which is only one of many that are suitable for expressing I-FLICE-2 protein, is available commercially from QIAGEN, Inc.. supra. Transformants are identified by their ability to grow on LB plates in the presence of ampicillin and kanamycin. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis. PCR and DNA sequencing. Clones containing the desired constructs are grown overnight ("O/N") in liquid culture in LB media supplemented with both ampicillin (100 μg/ml) and kanamycin (25 μg/ml). The O/N culture is used to inoculate a large culture, at a dilution of approximately 1 :25 to 1 :250. The cells are grown to an optical density at 600 nm ("OD600") of between 0.4 and 0.6. Isopropyl-b-D- thiogalactopyranoside ("IPTG") is then added to a final concentration of 1 mM to induce transcription from the lac repressor sensitive promoter, by inactivating the lad repressor. Cells subsequently are incubated further for 3 to 4 hours. Cells then are harvested by centrifugation. The cells are then stirred for 3-4 hours at 4°C in 6M guanidine-HCl, pH8. The cell debris is removed by centrifugation, and the supernatant containing the I-FLICE-2 is loaded onto a nickel-nitrilo-tri-acetic acid ("NiNTA") affinity resin column (available from QIAGEN, Inc., supra). Proteins with a 6 x His tag bind to the NI-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist, 1995, QIAGEN, Inc., supra). Briefly the supernatant is loaded onto the column in 6 M guanidine-HCl, pH8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH8, then washed with 10 volumes of 6 M guanidine-HCl pH6, and finally the I-FLICE-2 is eluted with 6 M guanidine-HCl, pH5. The purified protein is then renatured by dialyzing it against phosphate- buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80 °C. Example 2(a): Cloning and Expression of I-FLICE-1 protein in a Baculovirus Expression System In this illustrative example, the plasmid shuttle vector pA2 is used to insert the cloned DNA encoding the complete protein into a baculovirus to express the I-FLICE- 1 protein, using standard methods as described in Summers et al, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987). This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from E. coli under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate viable virus that express the cloned polynucleotide. Many other baculovirus vectors could be used in place of the vector above, such as pAc373, pVL941 and pAcIMl, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al. , Virology 170:31 -39. The cDNA sequence encoding the full length I-FLICΕ-1 protein in the deposited clone, including the AUG initiation codon shown in FIG. 1 A- IB (SΕQ ID NO:l), is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene. The 5' primer has the sequence: 5' CGCGGATCCGCCATCATGTCTGCTGAAGTCATC 3' (SΕQ ID NO:l l) containing the underlined BamHI restriction enzyme site, an efficient signal for initiation of translation in eukaryotic cells, as described by Kozak, M., J Mol Biol. 196:947-950 (1987), followed by 17 (i.e., 268-285) bases of the sequence of the complete I-FLICΕ-1 protein shown in FIG. 1A-1B, beginning with the AUG initiation codon. The 3' primer has the sequence: 5' CGCGGTACCGTGCTGGGATTACAGGTG 3' (SΕQ ID NO: 12) containing the underlined, Asp718 restriction site followed by 18 (1740-1758) nucleotides complementary to the 3' noncoding sequence in FIG. 1A-1B (SΕQ ID NO:l). The amplified fragment is isolated from a 1%> agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with BamHI and Asp718 and again is purified on a 1%> agarose gel. This fragment is designated herein "Fl". The plasmid is digested with the restriction enzymes BamHI and Asp718 and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1%> agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.). This vector DNA is designated herein "VI". Fragment Fl and the dephosphorylated plasmid VI are ligated together with T4 DNA ligase. E. coli HB101 or other suitable E. coli hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria are identified that contain the plasmid with the human I-FLICΕ-1 gene using the PCR method, in which one of the primers that is used to amplify the gene and the second primer is from well within the vector so that only those bacterial colonies containing the I-FLICΕ-1 gene fragment will show amplification of the DNA. The sequence of the cloned fragment is confirmed by DNA sequencing. This plasmid is designated herein pBac I-FLICΕ-1. Five μg of the plasmid pBac I-FLICΕ-1 is co-transfected with 1.0 μg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA.), using the lipofection method described by Feigner et al, Proc. Natl. Acad. Sci. USA 54:7413-7417 (1987). 1 μg of BaculoGold™ virus DNA and 5 μg of the plasmid pBac I-FLICΕ-1 are mixed in a sterile well of a microtiter plate containing 50 μl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is rocked back and forth to mix the newly added solution. The plate is then incubated for 5 hours at 27 °C. After 5 hours the transfection solution is removed from the plate and 1 ml of Grace's insect medium supplemented with 10%> fetal calf serum is added. The plate is put back into an incubator and cultivation is continued at 27 °C for four days. After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, supra. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10). After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4°C. The recombinant virus is called V- I-FLICE- 1. To verify the expression of the I-FLICE- 1 gene, Sf9 cells are grown in Grace's medium supplemented with 10%> heat inactivated FBS. The cells are infected with the recombinant baculovirus V- I-FLICE- 1 at a multiplicity of infection ("MOI") of about 2. Six hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). If radiolabeled proteins are desired, 42 hours later, 5 μCi of 35 S-methionine and 5 μCi 3 ^>-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then they are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled). Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the mature protein and thus the cleavage point and length of the secretory signal peptide. Example 2(b): Cloning and Expression of I-FLICE-2 protein in a Baculovirus Expression System In this illustrative example, the plasmid shuttle vector pA2 is used to insert the cloned DNA encoding the complete protein into a baculovirus to express the I-FLICE-2 protein, using standard methods as described in Summers et al, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987). This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from E. coli under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate viable virus that express the cloned polynucleotide. Many other baculovirus vectors could be used in place of the vector above, such as pAc373, pVL941 and pAcIMl, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al. , Virology 770:31 -39. The cDNA sequence encoding the full length I-FLICE-2 protein in the deposited clone, including the AUG initiation codon shown in FIG. 4A-4C (SEQ ID NO:6) is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene. The 5' primer has the sequence: 5' CGCGGATCCGCCATCATGGCAGAGATTGGTGAG 3' (SEQ ID NO: 13) containing the underlined BamHI restriction enzyme site, an efficient signal for initiation of translation in eukaryotic cells, as described by Kozak, M., J. Mol Biol. 196:947-950 (1987), followed by 17 (304-321) bases of the sequence of the complete I-FLICE-2 protein shown in FIG. 4A-4C, beginning with the AUG initiation codon. The 3' primer has the sequence: 5' CGCGGTACCAGAGCATGCAGTGTCAG 3' (SEQ ID NO: 14) containing the underlined, Asp718 restriction site followed by (i.e., 1400-1416) nucleotides complementary to the 3' noncoding sequence in FIG. 4A-4C (SEQ ID NO:5). The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with BamHI and Asp718 and again is purified on a 1%> agarose gel. This fragment is designated herein "Fl ". The plasmid is digested with the restriction enzymes BamHI and Asp718 and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.). This vector DNA is designated herein "VI ". Fragment Fl and the dephosphorylated plasmid VI are ligated together with T4 DNA ligase. E. coli HB101 or other suitable E. coli hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria are identified that contain the plasmid with the human I-FLICE-2 gene using the PCR method, in which one of the primers that is used to amplify the gene and the second primer is from well within the vector so that only those bacterial colonies containing the I-FLICE-2 gene fragment will show amplification of the DNA. The sequence of the cloned fragment is confirmed by DNA sequencing. This plasmid is designated herein pBac I-FLICE-2. Five μg of the plasmid pBac I-FLICE-2 is co-transfected with 1.0 μg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA.), using the lipofection method described by Feigner et al, Proc. Natl. Acad. Sci. USA 54:7413-7417 (1987). 1 μg of BaculoGold™ virus DNA and 5 μg of the plasmid pBac I-FLICE-2 are mixed in a sterile well of a microtiter plate containing 50 μl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is rocked back and forth to mix the newly added solution. The plate is then incubated for 5 hours at 27 °C. After 5 hours the transfection solution is removed from the plate and 1 ml of Grace's insect medium supplemented with 10%> fetal calf serum is added. The plate is put back into an incubator and cultivation is continued at 27 °C for four days. After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, supra. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10). After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4°C. The recombinant virus is called V-I-FLICE-2. To verify the expression of the I-FLICE-2 gene, Sf9 cells are grown in Grace's medium supplemented with 10% heat inactivated FBS. The cells are infected with the recombinant baculovirus V-I-FLICE-2 at a multiplicity of infection ("MOI") of about 2. Six hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). If radiolabeled proteins are desired, 42 hours later, 5 μCi of 35 S-methionine and 5 μCi 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then they are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled). Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the mature protein and thus the cleavage point and length of the secretory signal peptide. Example 3: Cloning and Expression of I-FLICE in Mammalian Cells A typical mammalian expression vector contains the promoter element, which mediates the initiation of transcription of mRNA, the protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription can be achieved with the early and late promoters from SV40, the long terminal repeats (LTRS) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter). Suitable expression vectors for use in practicing the present invention include, for example, vectors such as PSVL and PMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146) and pBC12MI (ATCC 67109). Mammalian host cells that could be used include, human HeLa 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV 1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells. Alternatively, the gene can be expressed in stable cell lines that contain the gene integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, or hygromycin allows the identification and isolation of the transfected cells. The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful to develop cell lines that carry several hundred or even several thousand copies of the gene of interest. Another useful selection marker is the enzyme glutamine synthase (GS) (Muφhy et al, Biochem J. 227:277-279 (1991); Bebbington et al, Bio/Technology 70:169-175 (1992)). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins. The expression vectors pCl and pC4 contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al, Molec. Cell. Biol. 5:438-447 (1985)) plus a fragment of the CMV-enhancer (Boshart et al, Cell 47:521-530 (1985)). Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, Xbal and Asp718, facilitate the cloning of the gene of interest. The vectors contain in addition the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene. Example 3(a): Cloning and Expression ofl-FLICE-l in COS Cells The expression plasmid, p I-FLICE- 1 HA, is made by cloning a cDNA encoding I-FLICE- 1 into the expression vector pcDNAI/Amp or pcDNAIII (which can be obtained from Invitrogen, Inc.). The expression vector pcDNAI/amp contains: (1) an E. coli origin of replication effective for propagation in E. coli and other prokaryotic cells; (2) an ampicillin resistance gene for selection of plasmid-containing prokaryotic cells; (3) an SV40 origin of replication for propagation in eukaryotic cells; (4) a CMV promoter, a polylinker, an SV40 intron; (5) several codons encoding a hemagglutinin fragment (i.e., an "HA" tag to facilitate purification) followed by a termination codon and polyadenylation signal arranged so that a cDNA can be conveniently placed under expression control of the CMV promoter and operably linked to the SV40 intron and the polyadenylation signal by means of restriction sites in the polylinker. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein described by Wilson et al, Cell 57:767-778 (1984). The fusion of the HA tag to the target protein allows easy detection and recovery of the recombinant protein with an antibody that recognizes the HA epitope. pcDNAIII contains, in addition, the selectable neomycin marker. A DNA fragment encoding the I-FLICE- 1 is cloned into the polylinker region of the vector so that recombinant protein expression is directed by the CMV promoter. The plasmid construction strategy is as follows. The I-FLICE- 1 cDNA of the deposited clone is amplified using primers that contain convenient restriction sites, much as described above for construction of vectors for expression of I-FLICE- 1 in E. coli. Suitable primers include the following, which are used in this example. The 5' primer, containing the underlined Smal site, a Kozak sequence, an AUG start codon and 17 bases of the 5' coding region of the complete I-FLICE- 1 has the following sequence: 5' CGCCCCGGGGCCATCATGTCTGCTGAAGTCATC (268-285) 3* (SEQ ID NO: 15). The 3' primer, containing the underlined Xbal site, a stop codon, and 18 bp of 3' coding sequence has the following sequence (at the 3' end): 5' CGC1CTAGATCAAGCGTAGTCTGGGACGTCGTATGGGTAGTGC TGGGATTACAGGTG (1740-1758) 3' (SEQ ID NO:16). The PCR amplified DNA fragment and the vector, pcDNAI/Amp, are digested with Smal and Xbal and then ligated. The ligation mixture is transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037), and the - transformed culture is plated on ampicillin media plates which then are incubated to allow growth of ampicillin resistant colonies. Plasmid DNA is isolated from resistant colonies and examined by restriction analysis or other means for the presence of the I-FLICE- 1 -encoding fragment. For expression of recombinant I-FLICE- 1, COS cells are transfected with an expression vector, as described above, using DEAE-DEXTRAN, as described, for instance, in Sambrook et al, Molecular Cloning: a Laboratory Manual, Cold Spring Laboratory Press, Cold Spring Harbor, New York (1989). Cells are incubated under conditions for expression of I-FLICE- 1 by the vector. Expression of the I-FLICE- 1 -HA fusion protein is detected by radiolabeling and immunoprecipitation, using methods described in, for example Harlow et al, Antibodies: A Laboratory Manual, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988). To this end, two days after transfection, the cells are labeled by incubation in media containing 35 S- cysteine for 8 hours. The cells and the media are collected, and the cells are washed and lysed with detergent-containing RIP A buffer: 150 mM NaCl, 1 %> NP- 40, 0.1% SDS, 0.5% DOC, 50 mM TRIS, pH 7.5, as described by Wilson et al. cited above. Proteins are precipitated from the cell lysate and from the culture media using an HA-specific monoclonal antibody. The precipitated proteins then are analyzed by SDS-PAGE and autoradiography. An expression product of the expected size is seen in the cell lysate, which is not seen in negative controls. Example 3(b): Cloning and Expression ofl-FLICE-l in CHO Cells The vector pC4 is used for the expression of I-FLICE- 1 protein. Plasmid pC4 is a derivative of the plasmid pSV2-dhfr (ATCC Accession No. 37146). The plasmid contains the mouse DHFR gene under control of the SV40 early promoter. Chinese hamster ovary- or other cells lacking dihydrofolate activity that are transfected with these plasmids can be selected by growing the cells in a selective medium (alpha minus MEM, Life Technologies) supplemented with the chemotherapeutic agent methotrexate. The amplification of the DHFR genes in cells resistant to methotrexate (MTX) has been well documented (see, e.g., Alt, F. W., Kellems, R. M., Bertino, J. R., and Schimke, R. T., 1978, J Biol. Chem. 255:1357-1370, Hamlin, J. L. and Ma, C. 1990, Biochem. et Biophys. Ada, 70 7:107-143, Page, M. J. and Sydenham, M.A. 1991, Biotechnology 9:64-68). Cells grown in increasing concentrations of MTX develop resistance to the drug by oveφroducing the target enzyme, DHFR, as a result of amplification of the DHFR gene. If a second gene is linked to the DHFR gene, it is usually co- amplified and over-expressed. It is known in the art that this approach may be used to develop cell lines carrying more than 1 ,000 copies of the amplified gene(s). Subsequently, when the methotrexate is withdrawn, cell lines are obtained which contain the amplified gene integrated into one or more chromosome(s) of the host cell. Plasmid pC4 contains for expressing the gene of interest the strong promoter of the long terminal repeat (LTR) of the Rous Sarcoma Virus (Cullen et al, Molec. Cell. Biol. 5:438-447 (1985)) plus a fragment isolated from the enhancer of the immediate early gene of human cytomegalovirus (CMV) (Boshart et al, Cell 47:521-530 (1985)). Downstream of the promoter are BamHI, Xbal, and Asp718 restriction enzyme cleavage sites that allow integration of the genes. Behind these cloning sites the plasmid contains the 3' intron and polyadenylation site of the rat preproinsulin gene. Other high efficiency promoters can also be used for the expression, e.g., the human β-actin promoter, the SV40 early or late promoters or the long terminal repeats from other retroviruses, e.g., HIV and HTLVI. Clontech's Tet-Off and Tet-On gene expression systems and similar systems can be used to express the I-FLICE- 1 in a regulated way in mammalian cells (Gossen, M., & Bujard, H. 1992, Proc. Natl Acad. Sci. USA 89: 5547- 5551). For the polyadenylation of the mRNA other signals, e.g., from the human growth hormone or globin genes can be used as well. Stable cell lines carrying a gene of interest integrated into the chromosomes can also be selected upon co- transfection with a selectable marker such as gpt, G418 or hygromycin. It is advantageous to use more than one selectable marker in the beginning, e.g., G418 plus methotrexate. The plasmid pC4 is digested with the restriction enzymes BamHI and Asp718 and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The vector is then isolated from a 1% agarose gel. The DNA sequence encoding the complete I-FLICE- 1 protein including its leader sequence is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene. The 5' primer has the sequence: 5 * CGCGGATCCGCCATCATGTCTGCTGAAGTCATC 3' (SEQ ID NO: 17) containing the underlined BamHI restriction enzyme site, an efficient signal for initiation of translation in eukaryotic cells, as described by Kozak, M., J. Mol Biol. 196:947-950 (1987), followed by 17 (i.e., 268-285) bases of the sequence of the complete I-FLICE-1 protein shown in FIG. 1A-1B, beginning with the AUG initiation codon. The 3' primer has the sequence: 5' CGCGG ACCGTGCTGGGATTACAGGTG 3' (SEQ ID NO: 18) containing the underlined, Asp718 restriction site followed by 18 (1740-1758) nucleotides complementary to the 3' noncoding sequence in FIG. 1A-1B (SEQ ID NO:l). The amplified fragment is digested with the endonucleases BamHI and Asp718 and then purified again on a 1%> agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. E. coli HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC4 using, for instance, restriction enzyme analysis. Chinese hamster ovary cells lacking an active DHFR gene are used for transfection. Five μg of the expression plasmid pC4 is cotransfected with 0.5 μg of the plasmid pSV2-neo using lipofectin (Feigner et al, supra). The plasmid pSV2neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μM, 2 μM, 5 μM, 10 μM, 20 μM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reverse phase HPLC analysis. Example 3(c): Cloning and Expression ofI-FLICE-2 in COS Cells The expression plasmid, pI-FLICE-2HA, is made by cloning a cDNA encoding I-FLICE-2 into the expression vector pcDNAI/Amp or pcDNAIII (which can be obtained from Invitrogen, Inc.). The expression vector pcDNAI/amp contains: (1) an E. coli origin of replication effective for propagation in E. coli and other prokaryotic cells; (2) an ampicillin resistance gene for selection of plasmid-containing prokaryotic cells; (3) an SV40 origin of replication for propagation in eukaryotic cells; (4) a CMV promoter, a polylinker, an SV40 intron; (5) several codons encoding a hemagglutinin fragment (i.e., an "HA" tag to facilitate purification) followed by a termination codon and polyadenylation signal arranged so that a cDNA can be conveniently placed under expression control of the CMV promoter and operably linked to the SV40 intron and the polyadenylation signal by means of restriction sites in the polylinker. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein described by Wilson et al, Cell 57:767-778 (1984). The fusion of the HA tag to the target protein allows easy detection and recovery of the recombinant protein with an antibody that recognizes the HA epitope. pcDNAIII contains, in addition, the selectable neomycin marker. A DNA fragment encoding the I-FLICE-2 is cloned into the polylinker region of the vector so that recombinant protein expression is directed by the CMV promoter. The plasmid construction strategy is as follows. The I-FLICE-2 cDNA of the deposited clone is amplified using primers that contain convenient restriction sites, much as described above for construction of vectors for expression of I-FLICE-2 in E. coli. Suitable primers include the following, which are used in this example. The 5' primer, containing the underlined BamHI site, a Kozak sequence, an AUG start codon and 17 codons of the 5' coding region of the complete I-FLICE-2 has the following sequence: 5' CGCGGATCCGCCATCATGGCAGAGATTGGTGAG 3' (SEQ ID NO: 19). The 3' primer, containing the underlined Xbal site, a stop codon, and 16 bp of 3' coding sequence has the following sequence (at the 3' end): 5'CGCTCTAGATCAAGCGTAGTCTGGGACGTCGTATGGGTAAGA GCATGCAGTGTCAG 3' (SEQ IDNO:20). The PCR amplified DNA fragment and the vector, pcDNAI/Amp, are digested with BamHI and Xbal and then ligated. The ligation mixture is transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037), and the - transformed culture is plated on ampicillin media plates which then are incubated to allow growth of ampicillin resistant colonies. Plasmid DNA is isolated from resistant colonies and examined by restriction analysis or other means for the presence of the I-FLICE-2-encoding fragment. For expression of recombinant I-FLICE-2, COS cells are transfected with an expression vector, as described above, using DEAE-DEXTRAN, as described, for instance, in Sambrook et al, Molecular Cloning: a Laboratory Manual, Cold Spring Laboratory Press, Cold Spring Harbor, New York (1989). Cells are incubated under conditions for expression of I-FLICE-2 by the vector. Expression of the I-FLICE-2-HA fusion protein is detected by radiolabeling and immunoprecipitation, using methods described in, for example Harlow et al, Antibodies: A Laboratory Manual, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988). To this end, two days after transfection, the cells are labeled by incubation in media containing 35 S- cysteine for 8 hours. The cells and the media are collected, and the cells are washed and lysed with detergent-containing RIPA buffer: 150 mM NaCl, 1 %> NP- 40, 0.1% SDS, 0.5% DOC, 50 mM TRIS, pH 7.5, as described by Wilson et al. cited above. Proteins are precipitated from the cell lysate and from the culture media using an HA-specific monoclonal antibody. The precipitated proteins then are analyzed by SDS-PAGE and autoradiography. An expression product of the expected size is seen in the cell lysate, which is not seen in negative controls. Example 3(d): Cloning and Expression ofI-FLICE-2 in CHO Cells The vector pC4 is used for the expression of I-FLICE-2 protein. Plasmid pC4 is a derivative of the plasmid pSV2-dhfr (ATCC Accession No. 37146). The plasmid contains the mouse DHFR gene under control of the SV40 early promoter. Chinese hamster ovary- or other cells lacking dihydrofolate activity that are transfected with these plasmids can be selected by growing the cells in a selective medium (alpha minus MEM, Life Technologies) supplemented with the chemotherapeutic agent methotrexate. The amplification of the DHFR genes in cells resistant to methotrexate (MTX) has been well documented (see, e.g., Alt, F. W., Kellems, R. M., Bertino, J. R., and Schimke, R. T., 1978, J Biol. Chem. 255:1357-1370, Hamlin, J. L. and Ma, C. 1990, Biochem. et Biophys. Acta, 7097:107-143, Page, M. J. and Sydenham, M.A. 1991, Biotechnology 9:64-68). Cells grown in increasing concentrations of MTX develop resistance to the drug by oveφroducing the target enzyme, DHFR, as a result of amplification of the DHFR gene. If a second gene is linked to the DHFR gene, it is usually co- amplified and over-expressed. It is known in the art that this approach may be used to develop cell lines carrying more than 1,000 copies of the amplified gene(s). Subsequently, when the methotrexate is withdrawn, cell lines are obtained which contain the amplified gene integrated into one or more chromosome(s) of the host cell. Plasmid pC4 contains for expressing the gene of interest the strong promoter of the long terminal repeat (LTR) of the Rous Sarcoma Virus (Cullen et al, Molec. Cell. Biol. 5:438-447 (1985)) plus a fragment isolated from the enhancer of the immediate early gene of human cytomegalovirus (CMV) (Boshart et al, Cell 47:521-530 (1985)). Downstream of the promoter are BamHI, Xbal, and Asp718 restriction enzyme cleavage sites that allow integration of the genes. Behind these cloning sites the plasmid contains the 3' intron and polyadenylation site of the rat preproinsulin gene. Other high efficiency promoters can also be used for the expression, e.g., the human β-actin promoter, the SV40 early or late promoters or the long terminal repeats from other retroviruses, e.g., HIV and HTLVI. Clontech's Tet-Off and Tet-On gene expression systems and similar systems can be used to express the I-FLICE-2 in a regulated way in mammalian cells (Gossen, M., & Bujard, H. 1992, Proc. Natl. Acad. Set. USA 59:5547-5551). For the polyadenylation of the mRNA other signals, e.g., from the human growth hormone or globin genes can be used as well. Stable cell lines carrying a gene of interest integrated into the chromosomes can also be selected upon co- transfection with a selectable marker such as gpt, G418 or hygromycin. It is advantageous to use more than one selectable marker in the beginning, e.g., G418 plus methotrexate. The plasmid pC4 is digested with the restriction enzymes BamHI/Asp718 and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The vector is then isolated from a 1%> agarose gel. The DNA sequence encoding the complete I-FLICE-2 protein sequence is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene. The 5' primer has the sequence: 5' CGCGGATCCGCCATCATGGCAGAGATTGGTGAG 3' (SEQ ID NO:21) containing the underlined BamHI restriction enzyme site, an efficient signal for initiation of translation in eukaryotic cells, as described by Kozak, M., J. Mol Biol. 196:947-950 (1987), followed by 17 (304-321) bases of the sequence of the complete I-FLICE-2 protein shown in FIG. 4A-4C, beginning with the AUG initiation codon. The 3' primer has the sequence: 5' CGCGGIACCAGAGCATGCAGTGTCAG 3' (SEQ ID NO:22) containing the underlined, Asp718 restriction site followed by (i.e., 1400-1416) nucleotides complementary to the 3' noncoding sequence in FIG. 4A-4C (SEQ ID NO:5). The amplified fragment is digested with the endonucleases BamHI and Asp718 and then purified again on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. E. coli HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC4 using, for instance, restriction enzyme analysis. Chinese hamster ovary cells lacking an active DHFR gene are used for transfection. Five μg of the expression plasmid pC4 is cotransfected with 0.5 μg of the plasmid pSV2-neo using lipofectin (Feigner et al, supra). The plasmid pSV2neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μM, 2 μM, 5 μM, 10 μM, 20 μM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reverse phase HPLC analysis. Example 4(a): Tissue distribution ofl-FLICE-l mRNA expression Northern blot analysis was carried out to examine I-FLICE- 1 gene expression in human tissues, using methods described by, among others, Sambrook et al, cited above. A cDNA probe containing the entire nucleotide sequence of the I-FLICE-1 protein (SEQ ID NO: 1) was labeled with 32 P using the DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe was purified using a CHROMA SPIN- 100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT 1200-1. The purified labeled probe was then used to examine various human tissues for I-FLICE- 1 mRNA. Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) were obtained from Clontech and were examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots were mounted and exposed to film at -70 °C overnight, and films developed according to standard procedures. Two transcripts were observed (7.5 kb and 6 kb) which presumably represent mRNA sequences encoding I-FLICE- 1 and I-FLICE-2. I-FLICE expression was identified in most tissues and cell lines examined except for the brain and the lymphoblastic leukemia line MOLT4. In particular, I-FLICE expression was evident in peripheral blood leukocytes, spleen, placenta and heart. Example 4(b): Tissue distribution ofI-FLICE-2 mRNA expression Northern blot analysis is carried out to examine I-FLICE-2 gene expression in human tissues, using methods described by, among others, Sambrook et al, cited above. A cDNA probe containing the entire nucleotide sequence of the I-FLICE-2 protein (SEQ ID NO: 6) is labeled with 32 P using the redip ή me™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using a CHROMA SPIN- 100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for I-FLICE-2 mRNA. Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) are obtained from Clontech and are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 °C overnight, and films developed according to standard procedures. Example 5: 1-FLICE-1 Associates with FLICE and Mch4/FLICE-2 Previous studies have shown that the DED domain is a protein interaction motif that mediates the binding of the adaptor molecule FADD to the effector proteases FLICE and Mch4/FLICE2 (Muzio et al, Cell 55:817-27 (1996); Chinnaiyan et al, Cell 57:505-12 (1995)). Given the striking structural similarity, the following experiment was performed to determine whether I-FLICE- 1 interacted with either FADD or other FLICE-like caspases. Materials and Methods Cell Lines and Expression Vectors - Human embryonic kidney 293, 293T and 293-EBNA cells were cultured to Dulbecco's modified Eagle's medium containing 10%) fetal bovine serum, nonessential amino acids, L-glutamine, and penicillin/streptomycin. Expression constructs were made in pcDNA3 or pcDNA3.1/MycHisA (Invitrogen) using standard recombinant methodologies (Sambrook, J. et al, Molecular Cloning 2nd Edition, Cold Spring Harbor Laboratory Press). Cloning ofl-FLICE-l - cDNAs corresponding to the partial open reading frame of I-FLICE- 1 were identified as sequences homologous to FLICE and Mch4/FLICE2 on searching the Human Genome Sciences data base using established EST methods (Adams, M.D. et al, Science 252:1651-1656 (1991) and Adams, M.D. et al, Nature 555:632-634 (1992)). Full length cDNAs were obtained by screening a random-primed human umbilical vein endothelial cell cDNA library constructed in the pcDNAl vector (Invitrogen). The sequence of I-FLICE- 1 was confirmed by sequencing plasmid DNA template on both strands by the dideoxy chain termination method employing modified T7 DNA polymerase (Sequenase, U.S. Biochemical Coφ.). Transfection, Coimmunoprecipitation and Western Analysis - Transient transfections of 293 T cells were performed as described previously (O'Rourke et al, J. Biol. Chem. 2(57:24921-24924 (1992)). Cells were harvested 40 hour following transfection, immunoprecipitation with α-FLAG or αmyc antibodies and analyzed by immunoblotting. Results and Discussion Sequence analysis of a full length cDNA revealed a 1443-base pair open reading frame that encoded a novel protein with a predicated molecular mass of 55.3 kDa (FIG. 1 A-1B). Given that the protein had striking homology to FLICE and Mch4/FLICE2 but lacked an active site, making it a potential dominant negative inhibitor, it was designated I-FLICE (for inhibitor of FLICE). The architecture of I-FLICE- 1 was strikingly similar to that of FLICE and Mch4/FLICE2, including two N-terminal DED-like tandem repeats and a region that resembled the caspase catalytic domain. Importantly, I-FLICE- 1 did not contain the catalytic cysteine that is normally embedded in the conserved pentapeptide QACRG or QACQG motif present in all known caspases. Rather, the pentapeptide sequence was QNYVV. In addition, based on the x-ray crystal structure of caspase- 1 (and caspase-3), amino acid residues His 237 (His 121 ), Gly 238 (Gly 122 ), and Cys 285 (Cys 163 ) are involved in catalysis, while residues Arg 179 (Arg 64 ), Gin 283 (Gin 161 ), Arg 341 (Arg 207 ), and Ser 347 (Ser 213 ) form a binding pocket for the carboxylate side chain of the PI aspartic acid (Wilson, K.P. et al, Nature 370:270-274 (1994), Rotonda, J. et al, Nat. Struct. Biol. 5:619-625 (1996), and Fraser, A. et al, Cell 55:781-784 (1996)). These seven residues are conserved in all caspases, but only three of them (Gly, Gin, and Ser) are found in I-FLICE- 1. Given this lack of conservation of key residues involved in catalysis and substrate binding it can be concluded that I-FLICE- 1 is not a cysteine protease and is incapable of binding Asp at the PI position. Interestingly, the DED domain of I-FLICE- 1 was more related to the corresponding domains present in the viral DED-containing inhibitors K13, MC159, and E8, sharing 34%>, 31%o, and 33%> identity (56%>, 51%>, and 44%> similarity), respectively (Hu, S. et al, J. Biol. Chem. 272:9621-9624 (1997) and Thome, M. etal, Nature 55(5:517-521 (1997)). Co-immunoprecipitation analysis revealed the ability of I-FLICE- 1 to bind FLICE and Mch4/FLICE2 but not FADD. In this respect, I-FLICE- 1 resembles the viral DED-containing molecule E8 in that it binds FLICE but not FADD (Hu et al, J. Biol. Chem. 272:9621-9624 (1997); Bertin et al, Proc. Natl. Acad. Sci. 94:1172-1176 (1997)). Since there was no association between I-FLICE-1 and FADD, I-FLICE- 1 was not recruited to the CD-95 or TNFR-1 signaling complex as evidenced by its inability to co-precipitate with these receptors. Example 6: Cell Death Assay Given the ability of the catalytically inactive I-FLICE- 1 to complex with FLICE-like caspases, the inventors reasoned that I-FLICE- 1 may be acting as a dominant negative inhibitor since the active form of all caspases is a tetramer derived from the processing of two zymogen forms to a four-chain assembly. It follows that a catalytically inert zymogen, such as I-FLICE- 1 , would be processed to inactive subunits that would result in the generation of a nonfunctional tetrameric protease. This mechanism predicts that I-FLICE- 1 should inhibit TNFR-1 and CD-95-induced apoptosis where FLICE-like caspases play an initiating role. The following cell death assay was performed. Materials and Methods Cell Death Assay - Human embryonic kidney 293 (for TNFR-1 killing) or 293 EBNA cells (for CD-95 killing) were transiently transfected with 0.1 μg of the reporter plasmid pCMV β-galactosidase plus 0.5μg of test plasmid in the presence or absence of 2.0μg of inhibitory plasmids. 22-24 hours after transfection, cells were fixed in 0.5% glutaraldehyde and stained with X-gal. Percentage of apoptotic cells was determined by calculating the fraction of membrane blebbed blue cells as a function of total blue cells. All assays were evaluated in duplicate and the mean and the standard deviation calculated. Results Consistent with the proposed mechanism, overexpression of I-FLICE- 1 resulted in substantial inhibition of TNFR-1 induced cell death comparable to previously characterized inhibitors including CrmA, MC 159, dominant negative FLICE (DNFLICE) and Mch4/FLICE2 (DNFLICE2) (see FIG. 6A). However, under the present experimental conditions, I-FLICE- 1 appeared to be a less potent inhibitor of CD-95 induced cell death, possibly reflecting the more potent death signal that emanates from this receptor (see FIG. 6B). It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims. The entire disclosure of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incoφorated by reference. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANTS: HUMAN GENOME SCIENCES, INC. 9410 KEY WEST AVENUE ROCKVILLE, MD 20850 UNITED STATES OF AMERICA THE REGENTS OF THE UNIVERSITY OF MICHIGAN WOLVERINE TOWER, ROOM 2071 3003 SOUTH STATE STREET ANN ARBOR, MI 48109 UNITED STATES OF AMERICA INVENTORS: NI, JIAN ROSEN, CRAIG A. DIXIT, VISHVA M. GENTZ, REINER L. KENNY, JOSEPH J. (ii) TITLE OF INVENTION: I-FLICE, A NOVEL INHIBITOR OF TUMOR NECROSIS FACTOR RECEPTOR-1 AND CD-95 INDUCED APOPTOSIS (iii) NUMBER OF SEQUENCES: 32 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. (B) STREET: 1100 NEW YORK AVENUE, SUITE 600 (C) CITY: WASHINGTON (D) STATE: DC (E) COUNTRY: US (F) ZIP: 20005 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: TO BE ASSIGNED (B) FILING DATE: HEREWITH (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/034,205 (B) FILING DATE: 21-JAN-1997 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/054,800 (B) FILING DATE: 05-AUG-1997 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: STEFFE, ERIC K. (B) REGISTRATION NUMBER: 36,688 (C) REFERENCE/DOCKET NUMBER: 1488.097PC02 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (202) 371-2600 (B) TELEFAX: (202) 371-2540 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2034 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 268..1707 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CGATCGCCCA GCACCAAGTC CGCTTCCAGG CTTTCGGTTT CTTTGCCTCC ATCTTGGGTG 60 CGCCTTCCCG GCGTCTAGGG GAGCGAAGGC TGAGGTGGCA GCGGCAGGAG AGTCCGGCCG 120 CGACAGGACG AACTCCCCCA CTGGAAAGGA TTCTGAAAGA AATGAAGTCA GCCCTCAGAA 180 ATGAAGTTGA CTGCCTGCTG GCTTTCTGTT GACTGGCCCG GAGCTGTACT GCAAGACCCT 240 TGTGAGCTTC CCTAGTCTAA GAGTAGG ATG TCT GCT GAA GTC ATC CAT CAG 291 Met Ser Ala Glu Val He His Gin 1 5 GTT GAA GAA GCA CTT GAT ACA GAT GAG AAG GAG ATG CTG CTC TTT TTG 339 Val Glu Glu Ala Leu Asp Thr Asp Glu Lys Glu Met Leu Leu Phe Leu 10 15 20 TGC CGG GAT GTT GCT ATA GAT GTG GTT CCA CCT AAT GTC AGG GAC CTT 387 Cys Arg Asp Val Ala He Asp Val Val Pro Pro Asn Val Arg Asp Leu 25 30 35 40 CTG GAT ATT TTA CGG GAA AGA GGT AAG CTG TCT GTC GGG GAC TTG GCT 435 Leu Asp He Leu Arg Glu Arg Gly Lys Leu Ser Val Gly Asp Leu Ala 45 50 55 GAA CTG CTC TAC AGA GTG AGG CGA TTT GAC CTG CTC AAA CGT ATC TTG 483 Glu Leu Leu Tyr Arg Val Arg Arg Phe Asp Leu Leu Lys Arg He Leu 60 65 70 AAG ATG GAC AGA AAA GCT GTG GAG ACC CAC CTG CTC AGG AAC CCT CAC 531 Lys Met Asp Arg Lys Ala Val Glu Thr His Leu Leu Arg Asn Pro His 75 80 85 CTT GTT TCG GAC TAT AGA GTG CTG ATG GCA GAG ATT GGT GAG GAT TTG 579 Leu Val Ser Asp Tyr Arg Val Leu Met Ala Glu He Gly Glu Asp Leu 90 95 100 GAT AAA TCT GAT GTG TCC TCA TTA ATT TTC CTC ATG AAG GAT TAC ATG 627 Asp Lys Ser Asp Val Ser Ser Leu He Phe Leu Met Lys Asp Tyr Met 105 110 115 120 GGC CGA GGC AAG ATA AGC AAG GAG AAG AGT TTC TTG GAC CTT GTG GTT 675 Gly Arg Gly Lys He Ser Lys Glu Lys Ser Phe Leu Asp Leu Val Val 125 130 135 GAG TTG GAG AAA CTA AAT CTG GTT GCC CCA GAT CAA CTG GAT TTA TTA 723 Glu Leu Glu Lys Leu Asn Leu Val Ala Pro Asp Gin Leu Asp Leu Leu 140 145 150 GAA AAA TGC CTA AAG AAC ATC CAC AGA ATA GAC CTG AAG ACA AAA ATC 771 Glu Lys Cys Leu Lys Asn He His Arg He Asp Leu Lys Thr Lys He 155 160 165 CAG AAG TAC AAG CAG TCT GTT CAA GGA GCA GGG ACA AGT TAC AGG AAT 819 Gin Lys Tyr Lys Gin Ser Val Gin Gly Ala Gly Thr Ser Tyr Arg Asn 170 175 180 GTT CTC CAA GCA GCA ATC CAA AAG AGT CTC AAG GAT CCT TCA AAT AAC 867 Val Leu Gin Ala Ala He Gin Lys Ser Leu Lys Asp Pro Ser Asn Asn 185 190 195 200 TTC AGG CTC CAT AAT GGG AGA AGT AAA GAA CAA AGA CTT AAG GAA CAG 915 Phe Arg Leu His Asn Gly Arg Ser Lys Glu Gin Arg Leu Lys Glu Gin 205 210 215 CTT GGC GCT CAA CAA GAA CCA GTG AAG AAA TCC ATT CAG GAA TCA GAA 963 Leu Gly Ala Gin Gin Glu Pro Val Lys Lys Ser He Gin Glu Ser Glu 220 225 230 GCT TTT TTG CCT CAG AGC ATA CCT GAA GAG AGA TAC AAG ATG AAG AGC 1011 Ala Phe Leu Pro Gin Ser He Pro Glu Glu Arg Tyr Lys Met Lys Ser 235 240 245 AAG CCC CTA GGA ATC TGC CTG ATA ATC GAT TGC ATT GGC AAT GAG ACA 1059 Lys Pro Leu Gly He Cys Leu He He Asp Cys He Gly Asn Glu Thr 250 255 260 GAG CTT CTT CGA GAC ACC TTC ACT TCC CTG GGC TAT GAA GTC CAG AAA 1107 Glu Leu Leu Arg Asp Thr Phe Thr Ser Leu Gly Tyr Glu Val Gin Lys 265 270 275 280 TTC TTG CAT CTC AGT ATG CAT GGT ATA TCC CAG ATT CTT GGC CAA TTT 1155 Phe Leu His Leu Ser Met His Gly He Ser Gin He Leu Gly Gin Phe 285 290 295 GCC TGT ATG CCC GAG CAC CGA GAC TAC GAC AGC TTT GTG TGT GTC CTG 1203 Ala Cys Met Pro Glu His Arg Asp Tyr Asp Ser Phe Val Cys Val Leu 300 305 310 GTG AGC CGA GGA GGC TCC CAG AGT GTG TAT GGT GTG GAT CAG ACT CAC 1251 Val Ser Arg Gly Gly Ser Gin Ser Val Tyr Gly Val Asp Gin Thr His 315 320 325 TCA GGG CTC CCC CTG CAT CAC ATC AGG AGG ATG TTC ATG GGA GAT TCA 1299 Ser Gly Leu Pro Leu His His He Arg Arg Met Phe Met Gly Asp Ser 330 335 340 TGC CCT TAT CTA GCA GGG AAG CCA AAG ATG TTT TTT ATT CAG AAC TAT 1347 Cys Pro Tyr Leu Ala Gly Lys Pro Lys Met Phe Phe He Gin Asn Tyr 345 350 355 360 GTG GTG TCA GAG GGC CAG CTG GAG GAC AGC AGC CTC TTG GAG GTG GAT 1395 Val Val Ser Glu Gly Gin Leu Glu Asp Ser Ser Leu Leu Glu Val Asp 365 370 375 GGG CCA GCG ATG AAG AAT GTG GAA TTC AAG GCT CAG AAG CGA GGG CTG 1443 Gly Pro Ala Met Lys Asn Val Glu Phe Lys Ala Gin Lys Arg Gly Leu 380 385 390 TGC ACA GTT CAC CGA GAA GCT GAC TTC TTC TGG AGC CTG TGT ACT GCG 1491 Cys Thr Val His Arg Glu Ala Asp Phe Phe Trp Ser Leu Cys Thr Ala 395 400 405 GAC ATG TCC CTG CTG GAG CAG TCT CAC AGC TCA CCG TCC CTG TAC CTG 1539 Asp Met Ser Leu Leu Glu Gin Ser His Ser Ser Pro Ser Leu Tyr Leu 410 415 420 CAG TGC CTC TCC CAG AAA CTG AGA CAA GAA AGA AAA CGC CCA CTC CTG 1587 Gin Cys Leu Ser Gin Lys Leu Arg Gin Glu Arg Lys Arg Pro Leu Leu 425 430 435 440 GAT CTT CAC ATT GAA CTC AAT GGC TAC ATG TAT GAT TGG AAC AGC AGA 1635 Asp Leu His He Glu Leu Asn Gly Tyr Met Tyr Asp Trp Asn Ser Arg 445 450 455 GTT TCT GCC AAG GAG AAA TAT TAT GTC TGG CTG CAG CAC ACT CTG AGA 1683 Val Ser Ala Lys Glu Lys Tyr Tyr Val Trp Leu Gin His Thr Leu Arg 460 465 470 AAG AAA CTT ATC CTC TCC TAC ACA TAAGAAACCA AAAGGCTGGG CGTAGTGGCT 1737 Lys Lys Leu He Leu Ser Tyr Thr 475 480 CGCACCTGTA ATCCCAGCAC TTTGGGAGGC CAAGGAGGGC GGATCACTTC AGGTCAGGAG 1797 TTCGAGACCA GCCTGGCCAA CATGGTAAAC GCTGTCCCTA GTAAGAGTGC AAAAATTAGC 1857 TGGGTGTGGG TGTGGGTACC TGTGTTCCCA GTTACTTGGG AGGCTGAGGT GGGAGGATCT 1917 TTTGAACCCA GGAGTTCAGG GTCATAGCAT GCTGTGATTG TGCCTACGAA TAGCCACTGC 1977 ATACCAACCT GGGCAATATA GCAAGATCCC ATCTTTTTAA AAAAAAAAAA AAAAAAA 2034 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 480 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Ser Ala Glu Val He His Gin Val Glu Glu Ala Leu Asp Thr Asp 1 5 10 15 Glu Lys Glu Met Leu Leu Phe Leu Cys Arg Asp Val Ala He Asp Val 20 25 30 Val Pro Pro Asn Val Arg Asp Leu Leu Asp He Leu Arg Glu Arg Gly 35 40 45 Lys Leu Ser Val Gly Asp Leu Ala Glu Leu Leu Tyr Arg Val Arg Arg 50 55 60 Phe Asp Leu Leu Lys Arg He Leu Lys Met Asp Arg Lys Ala Val Glu 65 70 75 80 Thr His Leu Leu Arg Asn Pro His Leu Val Ser Asp Tyr Arg Val Leu 85 90 95 Met Ala Glu He Gly Glu Asp Leu Asp Lys Ser Asp Val Ser Ser Leu 100 105 110 He Phe Leu Met Lys Asp Tyr Met Gly Arg Gly Lys He Ser Lys Glu 115 120 125 Lys Ser Phe Leu Asp Leu Val Val Glu Leu Glu Lys Leu Asn Leu Val 130 135 140 Ala Pro Asp Gin Leu Asp Leu Leu Glu Lys Cys Leu Lys Asn He His 145 150 155 160 Arg He Asp Leu Lys Thr Lys He Gin Lys Tyr Lys Gin Ser Val Gin 165 170 175 Gly Ala Gly Thr Ser Tyr Arg Asn Val Leu Gin Ala Ala He Gin Lys 180 185 190 Ser Leu Lys Asp Pro Ser Asn Asn Phe Arg Leu His Asn Gly Arg Ser 195 200 205 Lys Glu Gin Arg Leu Lys Glu Gin Leu Gly Ala Gin Gin Glu Pro Val 210 215 220 Lys Lys Ser He Gin Glu Ser Glu Ala Phe Leu Pro Gin Ser He Pro 225 230 235 240 Glu Glu Arg Tyr Lys Met Lys Ser Lys Pro Leu Gly He Cys Leu He 245 250 255 He Asp Cys He Gly Asn Glu Thr Glu Leu Leu Arg Asp Thr Phe Thr 260 265 270 Ser Leu Gly Tyr Glu Val Gin Lys Phe Leu His Leu Ser Met His Gly 275 280 285 He Ser Gin He Leu Gly Gin Phe Ala Cys Met Pro Glu His Arg Asp 290 295 300 Tyr Asp Ser Phe Val Cys Val Leu Val Ser Arg Gly Gly Ser Gin Ser 305 310 315 320 Val Tyr Gly Val Asp Gin Thr His Ser Gly Leu Pro Leu His His He 325 330 335 Arg Arg Met Phe Met Gly Asp Ser Cys Pro Tyr Leu Ala Gly Lys Pro 340 345 350 Lys Met Phe Phe He Gin Asn Tyr Val Val Ser Glu Gly Gin Leu Glu 355 360 365 Asp Ser Ser Leu Leu Glu Val Asp Gly Pro Ala Met Lys Asn Val Glu 370 375 380 Phe Lys Ala Gin Lys Arg Gly Leu Cys Thr Val His Arg Glu Ala Asp 385 390 395 400 Phe Phe Trp Ser Leu Cys Thr Ala Asp Met Ser Leu Leu Glu Gin Ser 405 410 415 His Ser Ser Pro Ser Leu Tyr Leu Gin Cys Leu Ser Gin Lys Leu Arg 420 425 430 Gln Glu Arg Lys Arg Pro Leu Leu Asp Leu His He Glu Leu Asn Gly 435 440 445 Tyr Met Tyr Asp Trp Asn Ser Arg Val Ser Ala Lys Glu Lys Tyr Tyr 450 455 460 Val Trp Leu Gin His Thr Leu Arg Lys Lys Leu He Leu Ser Tyr Thr 465 470 475 480 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 478 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Met Asp Phe Ser Arg Asn Leu Tyr Asp He Gly Glu Gin Leu Asp Ser 1 5 10 15 Glu Asp Leu Ala Ser Leu Lys Phe Leu Ser Leu Asp Tyr He Pro Gin 20 25 30 Arg Lys Gin Glu Pro He Lys Asp Ala Leu Met Leu Phe Gin Arg Leu 35 40 45 Gin Glu Lys Arg Met Leu Glu Glu Ser Asn Leu Ser Phe Leu Lys Glu 50 55 60 Leu Leu Phe Arg He Asn Arg Leu Asp Leu Leu He Thr Tyr Leu Asn 65 70 75 80 Thr Arg Lys Glu Glu Met Glu Arg Glu Leu Gin Thr Pro Gly Arg Ala 85 90 95 Gin He Ser Ala Tyr Arg Val Met Leu Tyr Gin He Ser Glu Glu Val 100 105 110 Ser Arg Ser Glu Leu Arg Ser Phe Lys Phe Leu Leu Gin Glu Glu He 115 120 125 Ser Lys Cys Lys Leu Asp Asp Asp Met Asn Leu Leu Asp He Phe He 130 135 140 Glu Met Glu Lys Arg Val He Leu Gly Glu Gly Lys Leu Asp He Leu 145 150 155 160 Lys Arg Val Cys Ala Gin He Asn Lys Ser Leu Leu Lys He He Asn 165 170 175 Asp Tyr Glu Glu Phe Ser Lys Glu Arg Ser Ser Ser Leu Glu Gly Ser 180 185 190 Pro Asp Glu Phe Ser Asn Gly Glu Glu Leu Cys Gly Val Met Thr He 195 200 205 Ser Asp Ser Pro Arg Glu Gin Asp Ser Glu Ser Gin Thr Leu Asp Lys 210 215 220 Val Tyr Gin Met Lys Ser Lys Pro Arg Gly Tyr Cys Leu He He Asn 225 230 235 240 Asn His Asn Phe Ala Lys Ala Arg Glu Lys Val Pro Lys Leu His Ser 245 250 255 He Arg Asp Arg Asn Gly Thr His Leu Asp Ala Gly Leu Thr Thr Thr 260 265 270 Phe Glu Glu Leu His Phe Glu He Lys Pro His Asp Asp Cys Thr Val 275 280 285 Glu Gin He Tyr Glu He Leu Lys He Tyr Gin Leu Met Asp His Ser 290 295 300 Asn Met Asp Cys Phe He Cys Cys He Leu Ser His Gly Asp Lys Gly 305 310 315 320 He He Tyr Gly Thr Asp Gly Gin Glu Pro Pro He Tyr Glu Leu Thr 325 330 335 Ser Gin Phe Thr Gly Leu Lys Cys Pro Ser Leu Ala Gly Lys Pro Lys 340 345 350 Val Phe Phe He Gin Ala Cys Gin Gly Asp Asn Tyr Gin Lys Gly He 355 360 365 Pro Val Glu Thr Asp Ser Glu Glu Gin Pro Tyr Leu Glu Met Asp Leu 370 375 380 Ser Ser Pro Gin Thr Arg Tyr He Pro Asp Glu Ala Asp Phe Leu Leu 385 390 395 400 Gly Met Ala Thr Val Asn Asn Cys Val Ser Tyr Arg Asn Pro Ala Glu 405 410 415 Gly Thr Trp Tyr He Gin Ser Leu Cys Gin Ser Leu Arg Glu Arg Cys 420 425 430 Pro Arg Gly Asp Asp He Leu Thr He Leu Thr Glu Val Asn Tyr Glu 435 440 445 Val Ser Asn Lys Asp Asp Lys Lys Asn Met Gly Lys Gin Met Pro Gin 450 455 460 Pro Thr Phe Thr Leu Arg Lys Lys Leu Val Phe Pro Ser Asp 465 470 475 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 479 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Met Lys Ser Gin Gly Gin His Trp Tyr Ser Ser Ser Asp Lys Asn Cys 1 5 10 15 Lys Val Ser Phe Arg Glu Lys Leu Leu He He Asp Ser Asn Leu Gly 20 25 30 Val Gin Asp Val Glu Asn Leu Lys Phe Leu Cys He Gly Leu Val Pro 35 40 45 Asn Lys Lys Leu Glu Lys Ser Ser Ser Ala Ser Asp Val Phe Glu His 50 55 60 Leu Leu Ala Glu Asp Leu Leu Ser Glu Glu Asp Pro Phe Phe Leu Ala 65 70 75 80 Glu Leu Leu Tyr He He Arg Gin Lys Lys Leu Leu Gin His Leu Asn 85 90 95 Cys Thr Lys Glu Glu Val Glu Arg Leu Leu Pro Thr Arg Gin Arg Val 100 105 110 Ser Leu Phe Arg Asn Leu Leu Tyr Glu Leu Ser Glu Gly He Asp Ser 115 120 125 Glu Asn Leu Lys Asp Met He Phe Leu Leu Lys Asp Ser Leu Pro Lys 130 135 140 Thr Glu Met Thr Ser Leu Ser Phe Leu Ala Phe Leu Glu Lys Gin Gly 145 150 155 160 Lys He Asp Glu Asp Asn Leu Thr Cys Leu Glu Asp Leu Cys Lys Thr 165 170 175 Val Val Pro Lys Leu Leu Arg Asn He Glu Lys Tyr Lys Arg Glu Lys 180 185 190 Ala He Gin He Val Thr Pro Pro Val Asp Lys Glu Ala Glu Ser Tyr 195 200 205 Gin Gly Glu Glu Glu Leu Val Ser Gin Thr Asp Val Lys Thr Phe Leu 210 215 220 Glu Ala Leu Pro Arg Ala Ala Val Tyr Arg Met Asn Arg Asn His Arg 225 230 235 240 Gly Leu Cys Val He Val Asn Asn His Ser Phe Thr Ser Leu Lys Asp 245 250 255 Arg Gin Gly Thr His Lys Asp Ala Glu He Leu Ser His Val Phe Gin 260 265 270 Trp Leu Gly Phe Thr Val His He His Asn Asn Val Thr Lys Val Glu 275 280 285 Met Glu Met Val Leu Gin Lys Gin Lys Cys Asn Pro Ala His Ala Asp 290 295 300 Gly Asp Cys Phe Val Phe Cys He Leu Thr His Gly Arg Phe Gly Ala 305 310 315 320 Val Tyr Ser Ser Asp Glu Ala Leu He Pro He Arg Glu He Met Ser 325 330 335 His Phe Thr Ala Leu Gin Cys Pro Arg Leu Ala Glu Lys Pro Lys Leu 340 345 350 Phe Phe He Gin Ala Cys Gin Gly Glu Glu He Gin Pro Ser Val Ser 355 360 365 He Glu Ala Asp Ala Leu Asn Pro Glu Gin Ala Pro Thr Ser Leu Gin 370 375 380 Asp Ser He Pro Ala Glu Ala Asp Phe Leu Leu Gly Leu Ala Thr Val 385 390 395 400 Pro Gly Tyr Val Ser Phe Arg His Val Glu Glu Gly Ser Trp Tyr He 405 410 415 Gin Ser Leu Cys Asn His Leu Lys Lys Leu Val Pro Arg His Glu Asp 420 425 430 He Leu Ser He Leu Thr Ala Val Asn Asp Asp Val Ser Arg Arg Val 435 440 445 Asp Lys Gin Gly Thr Lys Lys Gin Met Pro Gin Pro Ala Phe Thr Leu 450 455 460 Arg Lys Lys Leu Val Phe Pro Val Pro Leu Asp Ala Leu Ser He 465 470 475 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2597 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 304..1347 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: GCGAGCTTGC AGCCTCACCG ACGAGTCTCA ACTAAAAGGG ACTCCCGGAG CTAGGGGTGG 60 GGACTCGGCC TCACACAGTG ATTGCCGGCT ATTGGACTTT TGTCCAGTGA CAGCTGAGAC 120 AACAAGGACC ACGGGAGGAG GTGTAGGAGA GAAGCGCCGC GAACAGGCAT CGCCCAGCAC 180 CAAGTCCGCT TCCAGGCTTT CGGTTTCTTT GCCTCCATCT TGGGTGCGCC TTCCCGGCGT 240 CTAGGGGAGC GAAGGCTGAG GTGGCAGCGG CAGGAGAGTC CGGCCGCGAC AGGACGAGTG 300 CTG ATG GCA GAG ATT GGT GAG GAT TTG GAT AAA TCT GAT GTG TCC TCA 348 Met Ala Glu He Gly Glu Asp Leu Asp Lys Ser Asp Val Ser Ser 5 10 15 TTA ATT TTC CTC ATG AAG GAT TAC ATG GGC CGA GGC AAG ATA AGC AAG 396 Leu He Phe Leu Met Lys Asp Tyr Met Gly Arg Gly Lys He Ser Lys 20 25 30 GAG AAG AGT TTC TTG GAC CTT GTG GTT GAG TTG GAG AAA CTA AAT CTG 444 Glu Lys Ser Phe Leu Asp Leu Val Val Glu Leu Glu Lys Leu Asn Leu 35 40 45 GTT GCC CCA GAT CAA CTG GAT TTA TTA GAA AAA TGC CTA AAG AAC ATC 492 Val Ala Pro Asp Gin Leu Asp Leu Leu Glu Lys Cys Leu Lys Asn He 50 55 60 CAC AGA ATA GAC CTG AAG ACA AAA ATC CAG AAG TAC AAG CAG TCT GTT 540 His Arg He Asp Leu Lys Thr Lys He Gin Lys Tyr Lys Gin Ser Val 65 70 75 CAA GGA GCA GGG ACA AGT TAC AGG AAT GTT CTC CAA GCA GCA ATC CAA 588 Gin Gly Ala Gly Thr Ser Tyr Arg Asn Val Leu Gin Ala Ala He Gin 80 85 90 95 AAG AGT CTC AAG GAT CCT TCA AAT AAC TTC AGG GAA GAA CCA GTG AAG 636 Lys Ser Leu Lys Asp Pro Ser Asn Asn Phe Arg Glu Glu Pro Val Lys 100 105 110 AAA TCC ATT CAG GAA TCA GAA GCT TTT TTG CCT CAG AGC ATA CCT GAA 684 Lys Ser He Gin Glu Ser Glu Ala Phe Leu Pro Gin Ser He Pro Glu 115 120 125 GAG AGA TAC AAG ATG AAG AGC AAG CCC CTA GGA ATC TGC CTG ATA ATC 732 Glu Arg Tyr Lys Met Lys Ser Lys Pro Leu Gly He Cys Leu He He 130 135 140 GAT TGC ATT GGC AAT GAG ACA GAG CTT CTT CGA GAC ACC TTC ACT TCC 780 Asp Cys He Gly Asn Glu Thr Glu Leu Leu Arg Asp Thr Phe Thr Ser 145 150 155 CTG GGC TAT GAA GTC CAG AAA TTC TTG CAT CTC AGT ATG CAT GGT ATA 828 Leu Gly Tyr Glu Val Gin Lys Phe Leu His Leu Ser Met His Gly He 160 165 170 175 TCC CAG ATT CTT GGC CAA TTT GCC TGT ATG CCC GAG CAC CGA GAC TAC 876 Ser Gin He Leu Gly Gin Phe Ala Cys Met Pro Glu His Arg Asp Tyr 180 185 190 GAC AGC TTT GTG TGT GTC CTG GTG AGC CGA GGA GGC TCC CAG AGT GTG 924 Asp Ser Phe Val Cys Val Leu Val Ser Arg Gly Gly Ser Gin Ser Val 195 200 205 TAT GGT GTG GAT CAG ACT CAC TCA GGG CTC CCC CTG CAT CAC ATC AGG 972 Tyr Gly Val Asp Gin Thr His Ser Gly Leu Pro Leu His His He Arg 210 215 220 AGG ATG TTC ATG GGA GAT TCA TGC CCT TAT CTA GCA GGG AAG CCA AAG 1020 Arg Met Phe Met Gly Asp Ser Cys Pro Tyr Leu Ala Gly Lys Pro Lys 225 230 235 ATG TTT TTT ATT CAG AAC TAT GTG GTG TCA GAC GGC CAG CTG GAG GAC 1068 Met Phe Phe He Gin Asn Tyr Val Val Ser Asp Gly Gin Leu Glu Asp 240 245 250 255 AGC AGC CTC TTG GAG GTG GAT GGG CCA GCG ATG AAG AAT GTG GAA TTC 1116 Ser Ser Leu Leu Glu Val Asp Gly Pro Ala Met Lys Asn Val Glu Phe 260 265 270 AAG GCT CAG AAG CGA GGG CTG TGC ACA GTT CAC CGA GAA GCT GAC TTC 1164 Lys Ala Gin Lys Arg Gly Leu Cys Thr Val His Arg Glu Ala Asp Phe 275 280 285 TTC TGG AGC CTG TGT ACT GCG GAC ATG TCC CTG CTG GAG CAG TCT CAC 1212 Phe Trp Ser Leu Cys Thr Ala Asp Met Ser Leu Leu Glu Gin Ser His 290 295 300 AGC TCA CCG TCC CTG TAC CTG CAG TGC CTC TCC CAG AAA CTG AGA CAA 1260 Ser Ser Pro Ser Leu Tyr Leu Gin Cys Leu Ser Gin Lys Leu Arg Gin 305 310 315 GAA AGG GGG ACA ATT CCC GGA AGT GGA ATT ACA GAG TCA AAG GAC ATG 1308 Glu Arg Gly Thr He Pro Gly Ser Gly He Thr Glu Ser Lys Asp Met 320 325 330 335 CAT TTT TCA AGC CTC GGA TGC ATC TTA CTA GAT GTC CTA TAGGATGGTC 1357 His Phe Ser Ser Leu Gly Cys He Leu Leu Asp Val Leu 340 345 ATATCAGCTT TATAGGAGAG TAGCTGTGTC CCTGAATTCT CCCTGACACT GCATGCTCTT 1417 ATATTTCCTC AAGTTTTGAC AATTTGATAG GTGAAAAGTG GTATCTGACT GTTCAGATCT 1477 GGAAGGCTTT GTTATATAAA CATTTTTTTA ATGTTTATTG GCAAGAATAC TTTTCTAAGA 1537 GAAACATCAG TGAGCTGGTT TCCATTTAAG CTGAATGAAG CCACAATGTA CCTCAAGTAT 1597 AAGATTAACT GGCCTTTTTC AGTTGCACTC TAATTACAAT TTAGAATGAT GTTTCTGAGC 1657 CACCTGTCAA ATGCATTCTG GGCTGTACCT CTGCGTACCC CAGGAATAAA TCTCATGGCC 1717 TTCTTTACCT GGCCTCCTTA GTGGTGGCCC AGCAGGAAGC GGGGGTTAGA GCAGGAGCCA 1777 CTCAGCCTTC CAAGATAGAT ACTCCATGGG CCGGTGGTAT TACTGGCCTT TTGAGCCCAT 1837 CCCCATTTGC ATAGATGATC CACGTGGGTT ATCATCTGGC TGGTATGTTC CCAGAGTGAA 1897 ACTCAGCAGC CCCTTGAGGG AGGGGATGGT GGCCATCAGG CCAGAGTATT GCAAGTTAGT 1957 TTGGATCATT TGCTAAGCAG CTTGTGGTGC CTTCAGAAAG GAACAGTTTC AAAGAACTTT 2017 CACATCTGTT GGCTCATTTC GCCCTAATGA CAGTCTTCTC TTTGATATTT GCATGGCATT 2077 AAATTTTGCC TTTCTTGTTT TCTCCAGAAA ACGCCCACTC CTGGATCTTC ACATTGAACT 2137 CAATGGCTAC ATGTATGATT GGAACAGCAG AGTTTCTGCC AAGGAGAAAT ATTATGTCTG 2197 GCTGCAGCAC ACTCTGAGAA AGAAACTTAT CTCTCCTACA CATAAGAAAC CAAAAGGCTG 2257 GGCGTAGTGG CTCGCACCTG TGATCCCAGC ACTTTGGGAG GCCGAGGAGG GCGGATCACT 2317 TCAGGTCGGG AGTTCGAGAC CAGCCTGGCC AGCATGTGAA CGCTGTCCCT AGTAGAAGTG 2377 CAAAAATTGG CTGGTGTGGG TGTGGGTACC CTGTATTCCC AGTTGCTTGG GGGGCTGAGG 2437 TGGGAGGATC TTTTGACCCC AGGAGTTCAG GGTCATAGCA TGCTGTGATT GTGCCTACGA 2497 ATAGCCACTG CATACCAACC TGGGCAATAT AGCAAGATCC CATCTCTTTA AAAAAAAAAA 2557 AAAAAGGACA GGAACTATCT TAAAAAAAAA AAAAAAAAAA 2597 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 348 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Ala Glu He Gly Glu Asp Leu Asp Lys Ser Asp Val Ser Ser Leu 1 5 10 15 He Phe Leu Met Lys Asp Tyr Met Gly Arg Gly Lys He Ser Lys Glu 20 25 30 Lys Ser Phe Leu Asp Leu Val Val Glu Leu Glu Lys Leu Asn Leu Val 35 40 45 Ala Pro Asp Gin Leu Asp Leu Leu Glu Lys Cys Leu Lys Asn He His 50 55 60 Arg He Asp Leu Lys Thr Lys He Gin Lys Tyr Lys Gin Ser Val Gin 65 70 75 80 Gly Ala Gly Thr Ser Tyr Arg Asn Val Leu Gin Ala Ala He Gin Lys 85 90 95 Ser Leu Lys Asp Pro Ser Asn Asn Phe Arg Glu Glu Pro Val Lys Lys 100 105 110 Ser He Gin Glu Ser Glu Ala Phe Leu Pro Gin Ser He Pro Glu Glu 115 120 125 Arg Tyr Lys Met Lys Ser Lys Pro Leu Gly He Cys Leu He He Asp 130 135 140 Cys He Gly Asn Glu Thr Glu Leu Leu Arg Asp Thr Phe Thr Ser Leu 145 150 155 160 Gly Tyr Glu Val Gin Lys Phe Leu His Leu Ser Met His Gly He Ser 165 170 175 Gin He Leu Gly Gin Phe Ala Cys Met Pro Glu His Arg Asp Tyr Asp 180 185 190 Ser Phe Val Cys Val Leu Val Ser Arg Gly Gly Ser Gin Ser Val Tyr 195 200 205 Gly Val Asp Gin Thr His Ser Gly Leu Pro Leu His His He Arg Arg 210 215 220 Met Phe Met Gly Asp Ser Cys Pro Tyr Leu Ala Gly Lys Pro Lys Met 225 230 235 240 Phe Phe He Gin Asn Tyr Val Val Ser Asp Gly Gin Leu Glu Asp Ser 245 250 255 Ser Leu Leu Glu Val Asp Gly Pro Ala Met Lys Asn Val Glu Phe Lys 260 265 270 Ala Gin Lys Arg Gly Leu Cys Thr Val His Arg Glu Ala Asp Phe Phe 275 280 285 Trp Ser Leu Cys Thr Ala Asp Met Ser Leu Leu Glu Gin Ser His Ser 290 295 300 Ser Pro Ser Leu Tyr Leu Gin Cys Leu Ser Gin Lys Leu Arg Gin Glu 305 310 315 320 Arg Gly Thr He Pro Gly Ser Gly He Thr Glu Ser Lys Asp Met His 325 330 335 Phe Ser Ser Leu Gly Cys He Leu Leu Asp Val Leu 340 345 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: CGCCCATGGC TGAAGTCATC CATCAG 26 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: CGCAAGCTTG TGCTGGGATT ACAGGTG 27 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: CGCCCATGGA GATTGGTGAG GATTTG 26 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: CGCAAGCTTA GAGCATGCAG TGTCAG 26 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: CGCGGATCCG CCATCATGTC TGCTGAAGTC ATC 33 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: CGCGGTACCG TGCTGGGATT ACAGGTG 27 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: CGCGGATCCG CCATCATGGC AGAGATTGGT GAG 33 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: CGCGGTACCA GAGCATGCAG TGTCAG 26 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: CGCCCCGGGG CCATCATGTC TGCTGAAGTC ATC 33 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: CGCTCTAGAT CAAGCGTAGT CTGGGACGTC GTATGGGTAG TGCTGGGATT ACAGGTG 57 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: CGCGGATCCG CCATCATGTC TGCTGAAGTC ATC 33 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: CGCGGTACCG TGCTGGGATT ACAGGTG 27 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: CGCGGATCCG CCATCATGGC AGAGATTGGT GAG 33 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 56 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: CGCTCTAGAT CAAGCGTAGT CTGGGACGTC GTATGGGTAA GAGCATGCAG TGTCAG 56 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: CGCGGATCCG CCATCATGGC AGAGATTGGT GAG 33 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: CGCGGTACCA GAGCATGCAG TGTCAG 26 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 414 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: AATTCGGCAC GAGGGNGGAC TTGGCTGAAC TGCTCTACAG AGTGAGGCGA TTTGACCTGC 60 TCAAACGTAT CTTGAAGATG GACAGAAAAG CTGTGGAGAC CCACCTGCTC AGGAACCCTC 120 ACCTTGTTTC GGACTATAGA GTGCTGATGG CAGAGATTGG TGAGGATTTG GATAAATCTG 180 ATGTGTCCTC ATTAATTTTC CTCATGAAGG ATTACATGGG CCGAGGCAAG ATAAGCAAGG 240 AGAAGAGTTT CTTGGGACCT TGGTGGTTGA GTTGGGAGAA ACTAAATCTG GTTTGCCCCA 300 GATCAACTNG GGATTTNTTA GGAAAAATGC CTAAAGAACA TNCACAGGAT AGACCTGNAG 360 ACAAAANTCC AGNAGTACAN GCAGTNTGTT CAGGGAGCAG GGACAATTNC AGGA 414 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 393 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: TGCCAAGGAG AAATATTATG TCTGGCTGCA GCACACTCTG NGAAAGAAAC TTATCCTCTC 60 CTACACATAA GAAACCNAAA GGCTGGGCGT AGTGGCTCAC GCCTGTNAAT CCCAGCACTT 120 TGGGAGGCCA AGGAGGGCAG ATCACTTCAG GTCAGGAGTT CGAGACCAGC CTGGCCAACA 180 TGGTAAACGC TGTCCCTAGT AAAANTACAA AANTTAGCTG GGTGTGGGTG TGGGTACCTG 240 TGTTCCCAGT TACTTGGGAG GCTGAGGTGG GAGGATCTTT TGGAACCCAG GAGTTTCAGG 300 GTCATAGCAT GCTGTGNTTG TGCCCTNACG AATTAGCCAC TGCATTACCA ACCTGGGGCA 360 ATNTTAGGCA AGATCCCATN TNTTTTAAAA AAA 393 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 309 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: TGGATCTTCA CATTGAACTC AATGGCTACA TGTATGATTG GAACAGCAGA GTTTCTGCCA 60 AGGAGAAATA TTATGTCTGG CTGCAGCACA CTCTGAGAAA GAAACTTATC CTCTCCTACA 120 CATAAGAAAC CAAAAGGCTG GGCGTAGTGG CTCACGCCTG TGATCCCAGC ACTTTGGGAG 180 GCCGGGGAGG GCAGATCACT TCAGGTCAGG AGTTCGAGAC CGGCCTGGNC AACATGGTAG 240 ACGCTGTCCC TAGTAAAAAT GCAAAAGTTG GCTGGGTGTG GGTGTNGGTA CCTGTGTTCC 300 CAGTTGCTT 309 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 500 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: AATTCGGCAG AGCTCACTCA GGGCTCCCCC TGCATCACAT CAGGAGGATG TTCATGGGAG 60 ATTCATGCCC TTATCTAGCA GGGAAGCCAA AGATGTTTTT TATTCAGAAC TATGTGNTGT 120 CAGAGGGCCA GCTGGAGGAC AGCAGCCTCT TGGAGGTGGA TGGGCCAGCN ATGAAGAATG 180 TGGAATTCAA GGCTCAGAAG CGAGGGCTGT GCACAGTTCA CCGAGNAAGC TGACTTCTTC 240 TGGAGCCTGT GTAATGCGGA CATGTCCCTG CTTGGAGCAA TCTTCANAGG TTCANCGTCC 300 CTGTNACCTG CATGCCTTTT CCCAGAAACT GNGACAAGNA AGAAAACGNC CANTNCTGGG 360 GNTNTTTCAC ATTGGAACTC AATGGTTACA ANTTATGNTT GGGGNCAACA ANTTTTTTGC 420 CAAGGGGGAA TTTTTTGTTT TGGGNTGNAG AAAAATTTNG GGAAAGAANT TTTTCCCTTN 480 CNNNAAATTA GGNACCCAAA 500 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 324 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: ATTCTGAAAA AGAATGTGGG GTTTCCTTGC AGATGAGTTC ATCTGTTGTT TCATTTCCTT 60 TACAATAACT CCCCCACTGG AAAGGATTCT GAAAGAAATG AAGTCAGCCC TCAGAAATGA 120 AGTTGACTGC CTGCTGGCTT TCTGTTGACT GGCCTGGAGC TGTACTGCAA GACCCTTGTG 180 AGCTTCCCTA GTCTAAGAGT AGGATGTCTG CTGAAGTCAT CCATCAGGTT GAAGAAGCAC 240 TTGATACAGA TGAGAAGGAG ATGCTGCTCT TTTTGTGCCG GGATGTTGCT ATAGATGTGG 300 TTCCACCTAA TGTCAGGGAC CTTC 324 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 389 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: NAATTCGGCA GAGANAAGAG TCTCAAGGAT CCTTCAAATA ACTTCAGGCT CCATAATGGG 60 AGAAGTAAAG AACAAAGACT TAAGGAACAG CTTGGCGCTC AACAAGAACC AGTGNAAGAA 120 ATCCATTCAG GAATCAGAAG CTTTTTTGCC TCAGAGCATA CCTGAAGAGA GATACAAGAT 180 GAAGAGCAAG CCCCTAGGGA ATCTGCCTGA TAAATCGATT GCATTGGCAA TGAGGACAGA 240 GCTTCTTCGG GGACACCTTC ACTTCCCTGG GCTTATGAAG TNCCAGGAAA TTCTTGCATC 300 TCAGTATGCA TGGTATTNTC CCAGATTTTT TGGGNCCAAT TTGCCCGTTA TGNCCNGGGC 360 ANCNGGGGAT TTANGACAAT TTTGTGGTG 389 (2) INFORMATION FOR SEQ ID NO: 29: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 308 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (i ) MOLECULE TYPE: cDNA (xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 29: ATTCTGAAAA AGANTGNGGG GTTTCCTTGC AGATGAGTTC ATCTNTTGTT TCATTTCCTT 60 TACAATAACT CCCCCACTGG AAAGGATTCT GAAAGNAATG AAGTCAGCCC TCAGAAATGA 120 AGTTGNCTGC CTGCTGGCTT TCTGTTGACT GGCCTGGAGC TGTACTGCAA GACCCTTGTG 180 AGCTTCCCTA GTCTAAGAGT AGGATGTCTG CTGAAGTCAT CCATCAGGTT GAAGAAGCAC 240 TTGATACAGA TGAGAAGGAG ATGCTGCTCT TTTTGTGCCG GGATGTTTGC TATAGATGTG 300 GTTCCACC 308 (2) INFORMATION FOR SEQ ID NO: 30: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 297 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: ATTCTGAAAA AGAATGTGGG GTTTCCTNGC AGATGAGTTC ATCTGTTGTT TCATTTCCTT 60 TACAATAACT CCCCCACTGG AAAGGATTCT GAAAGAAATG AAGTCAGCCC TCAGAAATGA 120 AGTTGACTGC CTGCTGGCTT TCTGTTGACT GGCCTGGAGC TGTACTGCAA GACCCTTGTG 180 AGCTTCCCTA GTCTAAGAGT AGGATGTCTG CTGAAGTCAT CCATCAGGTT GAAGAAGCAC 240 TTGATACAGA TGAGAAGGAG ATGCTGCTCT TTTTTGTGCC GGGATGTTGC TATAGAT 297 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 348 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: TATAGGATGG TCATATCAGC TTTATAGGAG AGTAGCTGTG TCCCTGAATT CTCCCTGACA 60 CTGCATGCTC TTATATTTCC TCAAGTTTTG ACAATTTGAT AGGTGAAAAG TGGTATCTGA 120 CTGTTCAGAT CTGGAAGGCT TTGTTATATA AACATTTTTT TAATGTTTAT TGGCAAGAAT 180 ACTTTTCTAA GAGAAACATC AGTGAGCTGG TTTCCATTTA AGCTGAATGA AGCCACAATG 240 TACCTCAAGT ATAAGGTTAA CTGGCCTTTT TTCAGTTGCA CTCTAATTAC AATTTAGAAT 300 GATGTTTCTG AGCCACCTGT CAAATGCATT CTGGGGCTGT ACCTCTTG 348 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 333 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: TATAGGATGG TCATATCAGC TTTATAGGAG AGTAGCTGTG TCCCTGANTT CTCCCTGACA 60 CTGCATGCTC TTATATTTCC TCAAGTTTTG ACAATTTGAT AGGTGAAAAG TGGTATCTGA 120 CTGTNCAGAT CTGGAAGGCT TTGTTATATA AACATTTTTT TAATGTTTAT TGGCAAGAAT 180 ACTTTTCTAA GAGAAACATC AGTGAGCTGG TTTCCATTTA AGCTGAATGA AGCCACAATG 240 TACCTCANGT ATAAGGATTA ACTGGCCTTT TTCCAGTTGC ACTCTAATTA CAATTTTAGA 300 ATGATGTTCN GAGGCCACCT GTCAAATGCA TTC 333 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule \3bis) A. The indications made below relate to the microorganism referred to in the description on page 3 line 28 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ~~~ Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit Accession Number May 15, 1997 ATCC 209038 C. ADDITIONAL INDICATIONS (leave blank if not applicable) Tn ls information is continued on an additional sheet □ DNA Plasmid 1631454 D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE fthe indications are not for all designated States/ E. SEPARATE FURNISHING OF INDICATIONS (teme blank , fm, applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature ofthe indications e g "Accession Number of Deposit") For receiving Office use onl> For International Bureau use onh π Tihis sheet was received with the international application □ This sheet was received by the International Bureau on Authorized offi Authorized officer 'i nya Barnes PCT International Division Form PCT RO/134 (July 1992) PCTR0134 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule \3bis) A. The indications made below relate to the microorganism referred to in the description on page 4 line . B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ~~~ Name of depositary institution American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, Maryland 20852 United States of America Date of deposit Accession Number May 15, 1997 ATCC 209041 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet □ DNA Plasmid 1789630 D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if no, applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature ofthe indications, e.g., "Accession Number of Deposit") For receiving Office use only For International Bureau use onl\ This sheet was received with the international application ----- This sheet was received by the International Bureau on: Authorized officer Authorized officer ; . .. u ernational Division Form PCT RO/134 (July 1992) 097PCTRO.134

Claims: What Is Claimed Is: 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 480 in SEQ ID NO:2; (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 480 in SEQ ID NO:2; (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 348 in SEQ ID NO:6; (d) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 348 in SEQ ID NO:6; (e) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209038; (f) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209041; and (g) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), or (f). 2. An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e), (f), or (g) of claim 1 wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues. 3. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector. 4. A recombinant vector produced by the method of claim 3. 5. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 4 into a host cell. 6. A recombinant host cell produced by the method of claim 5. 7. A recombinant method for producing an I-FLICE- 1 or I-FLICE-2 polypeptide, comprising culturing the recombinant host cell of claim 6 under conditions such that said polypeptide is expressed and recovering said polypeptide. 8. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95%> identical to a sequence selected from the group consisting of: (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 75 in SEQ ID NO:2; (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 91 to about 171 in SEQ ID NO:2; (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 172 to about 375 in SEQ ID NO:2; (d) a nucleotide sequence encoding a polypeptide comprising amino acids from about 376 to about 480 in SEQ ID NO:2; (e) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 75 in SEQ ID NO:6; (f) a nucleotide sequence encoding a polypeptide comprising amino acids from about 76 to about 252 in SEQ ID NO:6; (f) a nucleotide sequence encoding a polypeptide comprising amino acids from about 253 to about 348 in SEQ ID NO:6; and (g) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), or (f). 9. An isolated I-FLICE- 1 or I-FLICE-2 polypeptide having an amino acid sequence at least 95 % identical to a sequence selected from the group consisting of: (a) amino acids from about 1 to about 480 in SEQ ID NO:2; (b) amino acids from about 2 to about 480 in SEQ ID NO:2; (c) amino acids from about 1 to about 348 in SEQ ID NO:6; (d) amino acids from about 2 to about 348 in SEQ ID NO:6; (e) the amino acid sequence of the I-FLICE- 1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209038; (f) the amino acid sequence of the I-FLICE-2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209041; and (g) the amino acid sequence of an epitope-bearing portion of any one ofthe polypeptides of (a), (b), (c), (d), (e), or (f). 10. An isolated antibody that binds specifically to an I-FLICE- 1 or I-FLICE-2 polypeptide of claim 9. 11. A method for treating diseases and disorders associated with apoptosis comprising administering to said individual a composition comprising an isolated polypeptide of claim 9. 12. A method useful during the diagnosis of diseases and disorders associated with aberrant cell survival in an individual comprising: (a) measuring I-FLICE- 1 or I-FLICE-2 gene expression level in cells or body fluid of said individual; (b) comparing the I-FLICE- 1 or I-FLICE-2 gene expression level of said individual with a standard I-FLICE- 1 or I-FLICE-2 gene expression level, whereby an increase or decrease in the I-FLICE- 1 or I-FLICE-2 gene expression level of said individual compared to said standard expression level is indicative of disease or disorder associated with aberrant cell survival. 13. An isolated nucleic acid molecule comprising a polynucleotide encoding an I-FLICE- 1 or I-FLICE-2 polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has a sequence selected from the group consisting of: (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 480 in SEQ ID NO:2; (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 480 in SEQ ID NO:2; (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 348 in SEQ ID NO:6; (d) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 348 in SEQ ID NO:6; (e) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209038; (f) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209041; and (g) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), or (f). 14. An isolated I-FLICE- 1 or I-FLICE-2 polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has a sequence selected from the group consisting of: (a) amino acids from about 1 to about 480 in SEQ ID NO:2 (b) amino acids from about 2 to about 480 in SEQ ID NO:2 (c) amino acids from about 1 to about 348 in SEQ ID NO:6 (d) amino acids from about 2 to about 348 in SEQ ID NO:6 (e) the amino acid sequence of the I-FLICE- 1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209038; (f) the amino acid sequence of the I-FLICE-2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209041 ; and (g) the amino acid sequence of an epitope-bearing portion of any one ofthe polypeptides of (a), (b), (c), (d), (e), or (f). 15. An isolated I-FLICE- 1 or I-FLICE-2 polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of: (a) amino acids from about 1 to about 75 in SEQ ID NO:2; (b) amino acids ' from about 91 to about 171 in SEQ ID NO:2 (c) amino acids from about 172 to about 375 in SEQ ID NO:2 (d) amino acids from about 376 to about 480 in SEQ ID NO:2 (e) amino acids from about 1 to about 75 in SEQ ID NO:6; (f) amino acids from about 76 to about 252 in SEQ ID NO:6; (g) amino acids from about 253 to about 348 in SEQ ID NO:6; and (h) the amino acid sequence of an epitope-bearing portion of any one ofthe polypeptides of (a), (b), (c), (d), (e), (f), or (g).

Inventors: DIXIT VISHVA M, GENTZ REINER L, KENNY JOSEPH J, NI JIAN, ROSEN CRAIG A, DIXIT, VISHVA, M., GENTZ, REINER, L., KENNY, JOSEPH, J., NI, JIAN, ROSEN, CRAIG, A.
Applicants: HUMAN GENOME SCIENCES INC, UNIV MICHIGAN, HUMAN GENOME SCIENCES, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Application year: 1998
Main classification: C12N15
IPC codes: A61K38, A61K45, A61P43, C07K16, C12N1, C12N5, C12N9, C12N15, C12Q1